Page last updated: 2024-11-04

oleic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Oleic Acid: An unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. It is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (Stedman, 26th ed) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

oleic acid : An octadec-9-enoic acid in which the double bond at C-9 has Z (cis) stereochemistry. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445639
CHEMBL ID8659
CHEBI ID16196
SCHEMBL ID1138
MeSH IDM0028734

Synonyms (279)

Synonym
MLS002153498
oleicacid
oleaic acid
bdbm50150484
gtpl1054
c18:1
oelsaeure
CHEBI:16196 ,
fa 18:1
cis-delta(9)-octadecenoic acid
(9z)- octadecenoic acid
oleic acid, >=99% (gc)
ccris 682
l'acide oleique [french]
epa pesticide chemical code 031702
wecoline oo (van)
nsc 9856
9-octadecenoic acid (9z)-
caswell no. 619
acide oleique [french]
naa 35
oleic acid, pure
oleinic acid
oleic acid (natural)
pamolyn
cis-delta(sup 9)-octadecenoic acid
brn 1726542
einecs 204-007-1
ai3-01291
HSCI1_000362
emersol 233ll
groco 2
oleine 7503
hy-phi 2088
vopcolene 27
9-octadecenoic acid, cis-
cis-octadec-9-enoic acid
groco 6
cis-.delta.(sup 9)-octadecenoic acid
hy-phi 1055
hy-phi 1088
wecoline oo
z-9-octadecenoic acid
l'acide oleique
emersol 221 low titer white oleic acid
cis-.delta.9-octadecenoic acid
nsc9856 ,
hy-phi 2066
9-octadecenoic acid, (z)-
pamolyn 100
emersol 213
emersol 210
nsc-9856
groco 5l
elaidoic acid
oelsauere
.delta.9-cis-oleic acid
9,10-octadecenoic acid
emersol 220 white oleic acid
glycon wo
emersol 6321
emersol 211
k 52
groco 4
cis-.delta.9-octadecenoate
glycon ro
tego-oleic 130
9-octadecenoic acid (z)-
hy-phi 2102
metaupon
wln: qv8u9-c
OLE ,
oleic acid, meets analytical specification of ph, eur., 65.0-88.0% (gc)
cis-oleate
elaic acid
9-octadecylenic acid
LMFA01030002
rapinic acid
c18:1n-9
18:1(n-9)
extra oleic 90
priolene 6928
lunac oa
edenor atio5
emersol 233
extra olein 90r
extra olein 80
oleic acid (8ci)
extra oleic 99
extra oleic 80r
9-octadecenoic-9,10-t2 acid, (9z)- (9ci)
d 100
fema number 2815
9-octadecenoic acid (9z)- (9ci)
hsdb 1240
industrene 206
elainic acid
delta9-cis-octadecenoic acid
9-cis-octadecenoic acid
lunac o-p
lunac o-ll
extraolein 90
industrene 205
lunac o-ca
priolene 6906
edenor ftio5
priolene 6907
emersol 205
priolene 6930
9z-octadecenoic acid
priolene 6933
emersol 213nf
white oleic acid
industrene 105
9-octadecenoic-9,10-t2 acid, (z)-
emersol 214nf
wochem no. 320
oleic acid-9,10-t
9-octadecenoic acid, (9z)-
cis-9-octadecenoic-9,10-3h2 acid
fema no. 2815
delta9-cis-oleic acid
emersol 6313nf
NCGC00091119-01
cis-9-octadecenoic acid
112-80-1
(9z)-octadecenoic acid
18:1delta9cis
18:1 n-9
(9z)-octadec-9-enoic acid
cis-delta9-octadecenoic acid
(z)-octadec-9-enoic acid
oleic acid
c18:1 n-9
cis-oleic acid
C00712
oleic acid, >=93% (gc)
oleic acid, suitable for cell culture, bioreagent
oleic acid-water soluble, powder, bioreagent, suitable for cell culture
oleic acid, natural, fcc
1G74
1VYF
1GNI
1HMS
oleic acid (nf)
D02315
oleic acid, technical grade, 90%
NCGC00091119-02
MLS001056779
smr000326739
cis 9 octadecenoic acid
9 octadecenoic acid
459CE4C0-C836-4249-8E2D-69874B714E9C
MLS002454427
CHEMBL8659 ,
priolene 6936
O0180
O0011
NCGC00091119-03
4-02-00-01641 (beilstein handbook reference)
unii-2umi9u37cp
oleic acid [nf]
acide oleique
2umi9u37cp ,
dtxcid705809
NCGC00257233-01
cas-112-80-1
tox21_303324
dtxsid1025809 ,
NCGC00259516-01
tox21_201967
99148-48-8
tox21_111086
HMS2234O13
einecs 270-164-8
9-octadecenoic acid (z)-, sulfurized
68412-07-7
9-octadecenoic acid (9z)-, sulfurized
sulfurized oleic acid
sulphurized oleic acid
oleic acid, sulfurized
S4707
(9z)-9-octadecenoic acid
REGID_FOR_CID_445639
oleic acid [mi]
oleic acid [vandf]
oleic acid [usp-rs]
oleic acid [who-dd]
oleic acid [ep monograph]
endocine component oleic acid
oleic acid [hsdb]
oleic acid (constituent of spirulina) [dsc]
oleic acid [ii]
oleic acid (constituent of saw palmetto) [dsc]
oleic acid [mart.]
oleic acid [fcc]
oleic acid [fhfi]
oleic acid [inci]
EPITOPE ID:187036
2LKK
AKOS017343225
SCHEMBL1138
z-octadeca-9-enoic acid
(9z)-9-octadecenoic acid #
(z)-9-octadecanoic acid
emersol 6313 nf
9-(z)-octadecenoic acid
AC-33767
HMS3649H21
AB00641912_08
mfcd00064242
oleic acid, certified reference material, tracecert(r)
oleic acid, analytical standard
oleic acid, from suet, natural, >=60% (gc)
F0001-0262
oleic acid, selectophore(tm), >=99.0%
oleic acid, saj first grade, >=70.0%
oleic acid, united states pharmacopeia (usp) reference standard
oleic acid, p.a.
oleic acid, european pharmacopoeia (ep) reference standard
oleic acid, technical grade
oleic acid, pharmaceutical secondary standard; certified reference material
oleic acid; (z)-octadec-9-enoic acid
emersol 6333 nf
9-(z)-octadecenoate
emersol 220 white oleate
industrene 104
priolene 6900
z-9-octadecenoate
9,10-octadecenoate
cis-octadec-9-enoate
pamolyn 100 fgk
pamolyn 125
oleic acid extra pure
emersol 7021
pamolyn 100 fg
(9z)-9-octadecenoate
emersol 221 low titer white oleate
(z)-9-octadecanoate
distoline
oleinate
CS-0016886
HY-N1446
oleic acid, natural, tech grade
BP-24023
AS-16066
SR-01000780573-6
sr-01000780573
oleic acid, natural
Q207688
HMS3885H18
CCG-267270
AT13415
oleic acid liquid
cis-9-octadecenoic acid;elainic acid
A894525
fa(18:1(9z))
EN300-306800
delta(9)-cis-oleic acid
oleic acid (constituent of flax seed oil)
fema number 2815.
oleic acid (ep monograph)
oleic acid (mart.)
oleic acid (c18:1) (constituent of krill oil)
oleic acid (constituent of saw palmetto)
oleic acid (ii)
oleic acid (constituent of spirulina)
usepa/opp pesticide code: 031702
cis-9-octadecanoic acid
naa 34
oleic acid (constituent of borage seed oil)
oleic acid (constituent of evening primrose oil)
fatty acid 18:1 n-9
cis-8-heptadecylenecarboxylic acid
cis-delta(sup 9)-octadecanoic acid
industrene 106
9,10-octadecanoic acid
9-octadecenoic acid(z)-,oxidized,sulfonated,sodium salts
Z2412194967

Research Excerpts

Toxicity

Oleic acid suppressed the toxic effects of palmitic acid on ER stress activation, lipoapoptosis and insulin resistance. In contrast to arachidonic acid, oleic Acid was not toxic to the Hep G2-MV2E1-9 cells.

ExcerptReferenceRelevance
"The underlying etiology of the toxic oil syndrome may be related to any of several toxic contaminants."( Synergistic vascular toxicity and fatty acid anilides in the toxic oil syndrome.
Ansari, GA; Boor, PJ; Jerrells, TR; Kaphalia, BS; Khan, MF, 1991
)
0.28
" Toxic effects of oxygen were observed almost exclusively in those cells of yeast mutants deficient in superoxide dismutase, which contain linolenic acid in cellular lipids."( Superoxide dismutase deficiency and the toxicity of the products of autooxidation of polyunsaturated fatty acids in yeast.
Bajus, A; Biliński, T; Błaszczyński, M; Litwińska, J, 1989
)
0.28
" pH-sensitive immunoliposomes containing diphtheria fragment A were not toxic to nontarget diphtheria-resistant A31 cells or to nontarget diphtheria-sensitive Vero cells."( Cytotoxicity of diphtheria toxin A fragment to toxin-resistant murine cells delivered by pH-sensitive immunoliposomes.
Collins, D; Huang, L, 1987
)
0.27
" Addition of an intracellular cholesterol transport inhibitor, either progesterone or U18666A, together with CP-113,818 blocked the toxic effect of CP-113,818."( Cell toxicity induced by inhibition of acyl coenzyme A:cholesterol acyltransferase and accumulation of unesterified cholesterol.
Bamberger, M; Johnson, WJ; Rothblat, GH; Stoudt, G; Warner, GJ, 1995
)
0.29
" In contrast to arachidonic acid, oleic acid was not toxic to the Hep G2-MV2E1-9 cells."( Cytotoxicity and apoptosis produced by arachidonic acid in Hep G2 cells overexpressing human cytochrome P4502E1.
Cederbaum, AI; Chen, Q; Galleano, M, 1997
)
0.3
" The spectral analysis demonstrated that other toxic fractions contained a number of halogenated compounds and PAHs."( Screening bioavailable hydrophobic toxicants in surface waters with semipermeable membrane devices: role of inherent oleic acid in toxicity evaluations.
Ellington, J; Sabaliunas, D; Sabaliuniene, I, 1999
)
0.3
" The ability of normal beta-cells to form and accumulate cytoplasmic triglycerides might serve as a cytoprotective mechanism against FFA-induced apoptosis by preventing a cellular rise in toxic free fatty acyl moieties."( Inverse relationship between cytotoxicity of free fatty acids in pancreatic islet cells and cellular triglyceride accumulation.
Cnop, M; Eizirik, DL; Hannaert, JC; Hoorens, A; Pipeleers, DG, 2001
)
0.31
"Evidence is presented herein that oleic acid is much less toxic to Jurkat cells than linoleic acid."( Comparative toxicity of oleic acid and linoleic acid on Jurkat cells.
Curi, R; Cury-Boaventura, MF; Pompéia, C, 2004
)
0.32
"Oleic acid was less toxic than linoleic acid to Raji cells."( Comparative toxicity of oleic acid and linoleic acid on Raji cells.
Curi, R; Cury-Boaventura, MF; Pompéia, C, 2005
)
0.33
" Evidence is presented herein that OA is less toxic to human lymphocytes than LA."( Comparative toxicity of oleic and linoleic acid on human lymphocytes.
Curi, R; Cury-Boaventura, MF; de Lima, TM; Gorjão, R; Newsholme, P, 2006
)
0.33
" Taken as whole, the toxic effect of the FA on insulin-producing RINm5F cells varied irrespective of the chain length and the degree of unsaturation."( Fatty acid-induced toxicity and neutral lipid accumulation in insulin-producing RINm5F cells.
Azevedo-Martins, AK; Curi, R; Lenzen, S; Lima, CL; Monteiro, AP, 2006
)
0.33
" Treating these cultures with caspase-3 inhibitor z-VAD-fmk did not protect the cells from MbetaCD toxic effects."( Characterization of methyl-beta-cyclodextrin toxicity in NGF-differentiated PC12 cell death.
Almaguel, FG; Bu, L; De Leon, M; Liu, JW; Padilla, A; Ulloth, JE, 2007
)
0.34
" Both emulsions were well tolerated with no adverse events observed."( Tolerability and safety of olive oil-based lipid emulsion in critically ill neonates: a blinded randomized trial.
Bines, JE; Croft, KD; Hardy, P; Heine, RG; Lee, O; Mori, TA; Peterkin, M; Shalley, H; Webb, AN,
)
0.13
" Hemolysis and acute toxicity investigations showed that BU-NLC was safe when given by intravenous injection with reduced toxicity."( The efficacy and safety of bufadienolides-loaded nanostructured lipid carriers.
He, H; Li, F; Tang, X; Wang, L; Weng, Y; Yang, J, 2010
)
0.36
" coli, siloxane-capped ZnO QDs appeared weakly toxic at lower doses (0."( Physicochemical properties and cellular toxicity of (poly)aminoalkoxysilanes-functionalized ZnO quantum dots.
Aboulaich, A; Guilloteau, H; Medjahdi, G; Mercier, C; Merlin, C; Schneider, R; Tilmaciu, CM, 2012
)
0.38
"The study determined the effect of intravenous administration of acutely toxic or sub-lethal doses of Na-oleate-coated Fe3O4 (OC-Fe3O4) nanoparticles (NPs) on liver structure and function in Wistar rats, compared to titanium dioxide (TiO2) NPs and saline-injected controls."( Health effects of selected nanoparticles in vivo: liver function and hepatotoxicity following intravenous injection of titanium dioxide and Na-oleate-coated iron oxide nanoparticles in rodents.
Dusinska, M; Handy, RD; Kebis, A; Kucharská, J; Pribojova, J; Staruchova, M; Tulinska, J; Ulicna, O; Volkovova, K, 2015
)
0.42
" This study developed a safe and effective formulation of THP, which has greater potential for clinic use in the tumor therapy."( Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin.
Gong, T; Li, M; Sun, X; Wu, W; Zhang, L; Zhang, X; Zhou, J, 2013
)
0.39
" The role of p66shc in adverse effects of OA was determined using knockdown, p66shc serine36 phosphorylation and cytochrome c binding-deficient cells."( Role of p66shc in renal toxicity of oleic acid.
Arany, I; Clark, JS; Dixit, M; Juncos, LA; Reed, DK, 2013
)
0.39
" No treatment-related mortalities or adverse effects occurred in general condition, body weight, food consumption, ophthalmology, urinalysis, hematology, clinical chemistry, gross pathology, organ weights or histopathology."( Safety evaluation of oleic-rich triglyceride oil produced by a heterotrophic microalgal fermentation process.
Bauter, MR; Carney, JR; Chan, T; Franklin, S; Green, R; Licari, P; Marone, PA; Matulka, RA; McQuaid, SL; Rakitsky, W; Szabo, NJ, 2014
)
0.4
" Oleic acid suppressed the toxic effects of palmitic acid on ER stress activation, lipoapoptosis and insulin resistance."( Role of hepatocyte S6K1 in palmitic acid-induced endoplasmic reticulum stress, lipotoxicity, insulin resistance and in oleic acid-induced protection.
González-Rodríguez, Á; Kozma, SC; Muntané, J; Pardo, V; Valverde, ÁM, 2015
)
0.42
" Whereas saturated fatty acids show a strong cytotoxic effect upon insulin-producing cells, unsaturated fatty acids are not toxic and can even prevent toxicity."( Antagonism Between Saturated and Unsaturated Fatty Acids in ROS Mediated Lipotoxicity in Rat Insulin-Producing Cells.
Elsner, M; Gehrmann, W; Jörns, A; Lenzen, S; Plötz, T; Würdemann, W, 2015
)
0.42
"The saturated NEFA palmitic acid had a significant toxic effect on the viability of rat insulin-producing cells."( Antagonism Between Saturated and Unsaturated Fatty Acids in ROS Mediated Lipotoxicity in Rat Insulin-Producing Cells.
Elsner, M; Gehrmann, W; Jörns, A; Lenzen, S; Plötz, T; Würdemann, W, 2015
)
0.42
"Saturated fatty acids are toxic to liver cells and are believed to play a central role in the pathogenesis of non-alcoholic steatohepatitis."( Differential hepatotoxicity of dietary and DNL-derived palmitate in the methionine-choline-deficient model of steatohepatitis.
Grenert, JP; Maher, JJ; Pickens, MK; Pierce, AA; Siao, K, 2015
)
0.42
" Dietary palmitate becomes toxic when combined with dietary sugar in the MCD model, presumably by enhancing hepatic de novo lipogenesis."( Differential hepatotoxicity of dietary and DNL-derived palmitate in the methionine-choline-deficient model of steatohepatitis.
Grenert, JP; Maher, JJ; Pickens, MK; Pierce, AA; Siao, K, 2015
)
0.42
" Understanding these effects is essential to establish satisfactory regulatory policies on the safe use of magnetite nanoparticles in biomedical applications."( In vitro cytotoxicity of superparamagnetic iron oxide nanoparticles on neuronal and glial cells. Evaluation of nanoparticle interference with viability tests.
Bessa, MJ; Brandão, F; Costa, C; Costa, S; Fernández-Bertólez, N; Kiliç, G; Laffon, B; Pásaro, E; Pereira, E; Quaresma, P; Teixeira, JP; Valdiglesias, V, 2016
)
0.43
" The results demonstrated a low photoreactivity and toxic effects lower than Aeroxide P25 of the nano-TiO2 powders, probably as a consequence of the presence of acidic moieties at the surface."( Surface reactivity and in vitro toxicity on human bronchial epithelial cells (BEAS-2B) of nanomaterials intermediates of the production of titania-based composites.
Aldieri, E; Carlucci, C; Ciccarella, G; Fenoglio, I; Marucco, A; Vergaro, V, 2016
)
0.43
" These data indicate that OA's protective effects do not require increased conversion of PA into inert TGs, but instead may be due to OA's ability to compete against PA for cellular uptake and/or esterification and, thereby, normalize the composition of cellular lipids in the presence of a toxic PA load."( Knockdown of triglyceride synthesis does not enhance palmitate lipotoxicity or prevent oleate-mediated rescue in rat hepatocytes.
Egnatchik, RA; Hasenour, CM; Leamy, AK; Patti, GJ; Shiota, M; Trenary, IA; Yao, CH; Young, JD, 2016
)
0.43
"Lipid droplets (LD) play a central role in lipid homeostasis by controlling transient fatty acid (FA) storage and release from triacylglycerols stores, while preventing high levels of cellular toxic lipids."( Perilipin 5 fine-tunes lipid oxidation to metabolic demand and protects against lipotoxicity in skeletal muscle.
Badin, PM; Bourlier, V; Guillou, H; Joanisse, DR; Langin, D; Laurens, C; Louche, K; Mairal, A; Marette, A; Montagner, A; Moro, C; Mouisel, E; Tremblay, A; Weisnagel, JS, 2016
)
0.43
" In vitro hemolytic studies and viability assays in kidney cells (HEK 293 cells) suggested that AmB in aggregated was state highly toxic but not AmB-OA."( Long chain fatty acid conjugation remarkably decreases the aggregation induced toxicity of Amphotericin B.
Jain, S; Prajapati, R; Sangamwar, AT; Thanki, K, 2018
)
0.48
" Redirecting the toxic saturated fatty acids into triglyceride storage and reduction of cholesterol accumulation might be the possible explanation of OA driven protection in this scenario."( Oleic acid protects saturated fatty acid mediated lipotoxicity in hepatocytes and rat of non-alcoholic steatohepatitis.
Chen, X; Chen, Y; Cheng, J; Li, L; Liao, G; Liu, J; Liu, X; Lu, Y; Luo, R, 2018
)
0.48
" These HEWL amyloids act as a sink for toxic OA micelles and their co-aggregate form large clumps, suggesting a protective function in amyloid and OA cytotoxicity."( HEWL interacts with dissipated oleic acid micelles, and decreases oleic acid cytotoxicity.
A Morozova-Roche, L; Huang, Q; Liu, Y; Sun, D; Zhang, C; Zubair Hussain, M, 2019
)
0.51
"Doxorubicin (DOX) is an anthracycline antibiotic widely used in the treatment of cancer, however, it is associated with the occurrence of adverse reactions that limits its clinical use."( Doxorubicin-loaded pH-sensitive micelles: A promising alternative to enhance antitumor activity and reduce toxicity.
Cassali, GD; Cavalcante, CH; Charlie-Silva, I; de Barros, ALB; de Oliveira Silva, J; Fernandes, RS; Leite, EA; Miranda Ferreira, LA; Ramos Oda, CM; Ventura Fernandes, BH, 2021
)
0.62
" High-sugar diets produce hyperglycemia, obesity, insulin resistance and cardiomyopathy in flies, along with ectopic accumulation of toxic lipids, or lipotoxicity."( Loss of Stearoyl-CoA desaturase 1 leads to cardiac dysfunction and lipotoxicity.
Musselman, LP; O'Hara, E; Quaglia, CJ; Tuthill Ii, BF, 2021
)
0.62
" splendens showed that they are scarcely toxic even at the maximum dosage of 1000 ppm (34."( Larvicidal and repellent activity of N-methyl-1-adamantylamine and oleic acid a major derivative of bael tree ethanol leaf extracts against dengue mosquito vector and their biosafety on natural predator.
Al Farraj, DA; Ali, AM; Chellappandian, M; Elshikh, MS; Hunter, WB; Kalaivani, K; Karthi, S; Senthil-Nathan, S; Vasantha-Srinivasan, P; Veerabahu, C, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
"To determine whether a portable sodium iodide (NaI) probe could provide a valid measure of the pulmonary half-life (T1/2) of aerosolized technetium-99m-diethylenetriaminepentaacetate (99mTc-DTPA, mol wt = 492) in small chests, we measured pulmonary clearance in rabbits using a gamma-scintillation camera and the portable probe."( Measurement of pulmonary clearance of radioaerosol using a portable sodium iodide probe.
Coates, G; Jefferies, AL; O'Brodovich, HM; Webber, CE, 1984
)
0.27
" The pharmacokinetic behaviors of three different SEDDS formulations (F2, F3, F4) were investigated in Beagle dogs."( Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo.
Quan, DQ; Xu, GX, 2007
)
0.34
" Compared with oral administration, maximum plasma concentration (Cmax) was significantly lower, and time to reach Cmax (Tmax) delayed with all formulated tenoxicam TDS."( Pharmacokinetics of formulated tenoxicam transdermal delivery systems.
Chun, I; Gwak, H; Kang, E; Kim, T, 2008
)
0.35
" The results of a pharmacokinetic study in beagle dogs showed improved absorption of CyA from cubic nanoparticles as compared to microemulsion-based Neoral((R)); higher C(max) (1371."( Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles.
Hu, F; Lai, J; Lu, Y; Wu, W; Yin, Z, 2010
)
0.36
" The dissolution of SEDDS was measured and its pharmacokinetic in rats was measured."( [Preparation of self-emulsifying soft capsule and its pharmacokinetic in rats for epimedium flavonoids].
Jiang, YN; Mo, HY, 2010
)
0.36
" The vesicles were characterized for physicochemical properties, ex vivo permeation using human skin and pharmacokinetic parameters and anti-inflammatory activity in rats."( Ceramide-2 nanovesicles for effective transdermal delivery: development, characterization and pharmacokinetic evaluation.
Bhandari, A; Gaur, PK; Kumar, Y; Mishra, S; Purohit, S, 2014
)
0.4
" The hepatic clearance kinetics determined based on the relaxometric quantification method indicated that both formulations exhibited a biphasic clearance process with a slow terminal clearance half-life of 11."( Benchtop MRI for pharmacokinetic evaluation of two aqueous-based nano-scaled formulations of oleic acid stabilized magnetite nanocrystals.
Belete, A; Maeder, K; Metz, H; Mueller, T, 2015
)
0.42
" The in vivo pharmacokinetic parameters and biodistribution of the nanoparticles containing PTX also indicated slower clearance, longer blood circulation and higher tumor selectivity."( Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel.
Lee, BJ; Tran, PH; Tran, TT, 2014
)
0.4
" Pharmacokinetic analysis showed a rapid uptake and complete metabolism of AITC following oral administration to rats."( Pharmacokinetics, Tissue Distribution, and Anti-Lipogenic/Adipogenic Effects of Allyl-Isothiocyanate Metabolites.
Ahn, J; Chung, WJ; Ha, TY; Jang, YJ; Jung, CH; Kim, YJ; Lee, DH; Moon, JH; Seong, KS, 2015
)
0.42
"This study investigated the preparation, characterization of physicochemical properties, ex vivo permeation using human skin, pharmacokinetic parameters and antihypertensive potential in rats, of nitrendipine-loaded nanovesicles of ceramide 2, stearic acid, behenic acid and cholesteryl sulfate containing oleic acid gel (NOVG)."( Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies.
Kumar Gaur, P; Mishra, S; Purohit, S, 2016
)
0.43
"The nanovesicles were made using film hydration method and characterized for physicochemical properties, ex vivo permeation using human skin, pharmacokinetic parameters and antihypertensive potential."( Nanovesicles of nitrendipine with lipid complex for transdermal delivery: pharmacokinetic and pharmacodynamic studies.
Kumar Gaur, P; Mishra, S; Purohit, S, 2016
)
0.43
"5 h according to the pharmacokinetic studies."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.43
" Additionally, in vivo pharmacokinetic study demonstrates an increase in Cmax (1."( Polymeric micelles based on amphiphilic oleic acid modified carboxymethyl chitosan for oral drug delivery of bcs class iv compound: Intestinal permeability and pharmacokinetic evaluation.
Kaur, S; Kumar, R; Roy, S; Samal, SK; Sangamwar, AT; Sirvi, A, 2020
)
0.56

Compound-Compound Interactions

ExcerptReferenceRelevance
" An unsaturated fatty acid (oleate) caused an increase in lipid fluidity of the surface membrane in MOLT-4 lymphoid cells, which possess higher lipid fluidity in combination with mannosamine, while saturated fatty acids had no effect on the fluidity properties of the membrane lipids (even in the presence of mannosamine)."( Antitumor activity of D-mannosamine in vitro: cytotoxic effect produced by mannosamine in combination with free fatty acids on human leukemia T-cell lines.
Harada, T; Morikawa, K; Morikawa, S; Onoda, T, 1985
)
0.27
" In this study, to develop therapeutic anti-HSV-2 agents, the most potent PEI combined with ~200 nm-sized liposomes with or without oleic acid (liposomes/PEI) was selected in vitro and further evaluated using in vivo studies."( Polyethylenimine combined with liposomes and with decreased numbers of primary amine residues strongly enhanced therapeutic antiviral efficiency against herpes simplex virus type 2 in a mouse model.
Akimoto, T; Aragane, D; Hayashi, K; Ishigaki, K; Iwamizu, M; Kai, T; Maitani, Y; Nakazawa, Y, 2013
)
0.39
"Multiphase food systems consist of complex interfacial layers where surface active molecules complete compete for adsorption and interact with one another affecting the interfacial properties and the behavior of the food systems involved."( Effect of oleic acid on the properties of protein adsorbed layers at water/oil interfaces: An EPR study combined with dynamic interfacial tension measurements.
Dimitreli, G; Georgiou, D; Kalogianni, EP; Nika, S; Papadimitriou, V; Sklaviadis, L; Theochari, I, 2017
)
0.46
"High-purity trilinolein and triolein were prepared by Novozym 435-catalyzed esterification reaction combined with column chromatography purification in this study."( Preparation of High-Purity Trilinolein and Triolein by Enzymatic Esterification Reaction Combined with Column Chromatography.
Chen, Z; Lan, T; Li, H; Pan, L; Wu, D; Zhao, B, 2019
)
0.51
" Treatment with near-infrared laser irradiation for five minutes combined with in situ administration of the nanoparticles showed a tumor volume reduction of approximately 80% and, in some cases, led to the formation of several necrotic foci, observed histologically."( Proof-of-Concept Study of Multifunctional Hybrid Nanoparticle System Combined with NIR Laser Irradiation for the Treatment of Melanoma.
Coelho, JMP; Faísca, P; Ferreira, D; Ferreira, H; Ferreira-Gonçalves, T; Figueiredo, IV; Gaspar, MM; Lopes, J; Reis, CP; Rodrigues, CMP; Silva, CO; Viana, AS, 2021
)
0.62

Bioavailability

Both dietary and labeled stearic acid were less well absorbed than either oleic or linoleic acids. Oleic acid's rate of absorption increased as the hydrogen ion and sodium taurocholate concentrations were increased or as the thickness and resistance of the unstirred water layer were diminished.

ExcerptReferenceRelevance
" The percent absolute bioavailability of the compound was enhanced from 3-6% (PEG 400 solution) to 15-27% when the emulsion formulations were used."( Enhancement of nasal delivery of a renin inhibitor in the rat using emulsion formulations.
Baron, DA; Belonio, B; Kararli, TT; Katz, B; Needham, TE; Schmidt, RE; Schoenhard, G, 1992
)
0.28
" They also can inhibit DHT binding to albumin, whereas DHT binding to SHBG is not altered, suggesting that FFA at physiological concentrations may be important regulators of bioavailability of T to tissues."( Effect of free fatty acids on the bioavailability of plasma testosterone and dihydrotestosterone.
Korenman, SG; Mooradian, AD; Pamplona, DM; Viosca, SP, 1988
)
0.27
" The bioavailability of cinnarizine from the oral administration of an oleic acid solution in a hard capsule was investigated and compared with that of a cinnarizine tablet, using beagle dogs."( Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs.
Kayano, M; Machida, Y; Nagai, T; Tatsuishi, K; Tokumura, T; Tsushima, Y, 1987
)
0.27
" Both dietary and labeled stearic acid were less well absorbed than either oleic or linoleic acids."( Whole body oxidation of dietary fatty acids: implications for energy utilization.
Clandinin, MT; Jones, PJ; Pencharz, PB, 1985
)
0.27
" Oleic acid's rate of absorption increased as the hydrogen ion and sodium taurocholate concentrations were increased or as the thickness and resistance of the unstirred water layer were diminished or following the addition of lysolecithin."( Intestinal absorption of free oleic acid in the unanesthetized rat: evidence for a saturable component?
Chow, SL; Dadufalza, VD; Hollander, D, 1984
)
0.27
"We have studied the effects of intraluminal pH on micellar solubilization and on absorption rate of oleic acid (OA) and cholesterol in proximal small bowel segments and the total small bowel in rats."( Effect of intraluminal pH on cholesterol and oleic acid absorption from micellar solutions in the rat.
Chijiiwa, K; Linscheer, WG, 1984
)
0.27
"Human blood selenium (Se) levels have been related to the types of food consumed, bioavailability of Se, and various disease states, including cancer."( Selenium status of vegeterians, nonvegetarians, and hormone-dependent cancer subjects.
Leklem, JE; Shultz, TD, 1983
)
0.27
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
"The authors investigated the effect of oleic acid (cis-9-octadecenoic acid) (OA), a lipidic carrier, on the intestinal absorption rate and T1 relaxation time of manganese (III) mesoporphyrin (Mn-mesoporphyrin), a prototype hepatobiliary contrast agent for magnetic resonance imaging."( Intestinal absorption of Mn-mesoporphyrin in a small bowel sac system: effect of oleic acid.
Dong, P; Ho, RJ; Nelson, JA; Schmiedl, UP; Starr, F; von Ingersleben, G, 1997
)
0.3
" UFAs were found to be well absorbed into tumor tissues after oral administration, causing marked changes in relative levels, the arachidonic acid (AA) content, in particular, being markedly decreased by treatment with DHA or EPA, but not with DHA plus EPA or with DHA plus LA."( Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities.
Araki, E; Asamoto, M; Iigo, M; Ishikawa, C; Kuhara, T; Kunimoto, T; Moore, MA; Suzuki, I; Tsuda, H; Yazawa, K, 1997
)
0.3
" The peak rate of absorption was significantly lower in LZ rats (67."( Marginal zinc deficiency lowers the lymphatic absorption of alpha-tocopherol in rats.
Kim, ES; Koo, SI; Noh, SK, 1998
)
0.3
"01) than those in the T group, with a comparative bioavailability of 115."( Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route.
Hashimoto, H; Kazui, T; Muhammad, BA; Suzuki, K; Suzuki, Y; Uno, T, 1999
)
0.3
" Chylomicron triglyceride results show that the deuterated fatty acids were equally well absorbed and diet did not influence absorption."( Effect of dietary docosahexaenoic acid on desaturation and uptake in vivo of isotope-labeled oleic, linoleic, and linolenic acids by male subjects.
Adlof, RO; Duval, SM; Emken, EA; Nelson, GJ, 1999
)
0.3
"The aim of this study was to evaluate the potential of an emulsion incorporating unsaturated fatty acids to improve the mucosal absorption of poorly absorbed drugs from rat intestinal loops in situ, using a water-in-oil-in-water (W/O/W) multiple emulsion."( Enhanced enteral bioavailability of vancomycin using water-in-oil-in-water multiple emulsion incorporating highly purified unsaturated fatty acid.
Chiba, Y; Kajita, M; Morishita, M; Nagai, T; Takayama, K; Tokiwa, S, 2000
)
0.31
"These results indicate marked differences in the ability of C18 fatty acids to reduce food intake that appear not to be related to rate of absorption but may partially be explained by CCK release."( The effects of intestinal infusion of long-chain fatty acids on food intake in humans.
Arnold, M; Conlon, CA; Francis, J; French, SJ; Meijer, G; Mutuma, ST; Read, NW, 2000
)
0.31
" The absorption rate of TEN increased in parallel with increasing OA concentration, due to the alteration of the stratum corneum caused by this enhancer."( Combined effect of oleic acid and propylene glycol on the percutaneous penetration of tenoxicam and its retention in the skin.
Arellano, A; Larrucea, E; Santoyo, S; Ygartua, P, 2001
)
0.31
"A study was carried out in human volunteers to investigate whether ileal brake activators could alter the bioavailability of atenolol from the small intestine by slowing intestinal transit and thereby increasing the time available for absorption."( The effect of ileal brake activators on the oral bioavailability of atenolol in man.
Chauhan, S; Davis, SS; Dobson, CL; Sparrow, RA; Wilding, IR, 2002
)
0.31
"05) and decreased microsomal triglyceride transfer protein (MTP) mRNA expression, suggesting that lipid bioavailability and lipidation of lipoprotein assembly are likely involved in decreased apoB secretion."( Microsomal triglyceride transfer protein gene expression and ApoB secretion are inhibited by bitter melon in HepG2 cells.
Adeli, K; Efird, JT; Nerurkar, PV; Nerurkar, VR; Pearson, L; Theriault, AG, 2005
)
0.33
"Improving the bioavailability of beta-carotene is vital to manage vitamin A deficiency."( Micellar oleic and eicosapentaenoic acid but not linoleic acid influences the beta-carotene uptake and its cleavage into retinol in rats.
Baskaran, V; Krishnakantha, TP; Lakshminarayana, R; Raju, M, 2006
)
0.33
" Therefore, we investigated whether fatty acids such as oleic acid and docosahexaenoic acid (DHA), both commonly present in food, negatively affect the integrity of tight junctions (TJ) in the intestinal epithelium and thereby increase the absorption of poorly absorbed hydrophilic substances."( Oleic acid and docosahexaenoic acid cause an increase in the paracellular absorption of hydrophilic compounds in an experimental model of human absorptive enterocytes.
Aspenström, P; Aspenström-Fagerlund, B; Glynn, AW; Ilbäck, NG; Ring, L; Tallkvist, J, 2007
)
0.34
" The bioavailability was compared using the pharmacokinetic parameters, peak plasma concentration (C(max)), time to reach peak plasma concentration (T(max)) and total area under the plasma concentration-time curve (AUC(0-t))."( Formulation optimization of self-emulsifying preparations of puerarin through self-emulsifying performances evaluation in vitro and pharmacokinetic studies in vivo.
Quan, DQ; Xu, GX, 2007
)
0.34
"This study reports on the results of repeated gavages and dietary feeding of lutein dispersed either in phospholipids or fatty acid micelles or vegetable oils and the effects on lutein bioavailability and antioxidant enzymes in rats."( Phospholipid, oleic acid micelles and dietary olive oil influence the lutein absorption and activity of antioxidant enzymes in rats.
Baskaran, V; Keshava Prakash, MN; Lakshminarayana, R; Raju, M, 2009
)
0.35
"Reactive oxygen species mediate a decrease in nitric oxide (NO) bioavailability and endothelial dysfunction, with secondary oxidized and nitrated by-products of these reactions contributing to the pathogenesis of numerous vascular diseases."( Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids.
Batthyany, C; Cole, MP; Freeman, BA; Golin-Bisello, F; Khoo, NK; Rudolph, V; Schopfer, FJ; Woodcock, SR, 2010
)
0.36
"Efforts to improve the oral bioavailability of cyclosporine A (CyA) remains a challenge in the field of drug delivery."( Pharmacokinetics and enhanced oral bioavailability in beagle dogs of cyclosporine A encapsulated in glyceryl monooleate/poloxamer 407 cubic nanoparticles.
Hu, F; Lai, J; Lu, Y; Wu, W; Yin, Z, 2010
)
0.36
" The results indicated that incorporation of antioxidants in this new SMEDDS not only significantly reduced ritonavir-induced ER stress activation, ROS production and apoptosis in intestinal epithelial cells and macrophages, but also improved the solubility, stability and bioavailability of ritonavir, and significantly reduced ritonavir-induced disruption of intestinal barrier function in vivo."( Development of a novel self-microemulsifying drug delivery system for reducing HIV protease inhibitor-induced intestinal epithelial barrier dysfunction.
Jin, F; Lei, B; Studer, EJ; Wang, G; Wang, X; Wang, Y; Wen, C; Zha, W; Zhang, L; Zhou, H, 2010
)
0.36
" LPs also decreased oleate-induced microsomal triglyceride transfer protein (MTTP) mRNA expression and cellular total cholesterol, suggesting that lipid bioavailability and lipidation of lipoprotein are likely involved in the decreased secretion of apo-B."( Lignophenols decrease oleate-induced apolipoprotein-B secretion in HepG2 cells.
Fujita, S; Funaoka, M; Mikame, K; Mukai, Y; Norikura, T; Sato, S, 2010
)
0.36
" Despite recent advances in the clinical development of azacytidine, the use of the drug is limited by its low bioavailability and dependency on variably expressed nucleoside transporters for cellular uptake."( Delivery of 5-azacytidine to human cancer cells by elaidic acid esterification increases therapeutic drug efficacy.
Brueckner, B; Fichtner, I; Hals, PA; Lyko, F; Markelova, MR; Rius, M; Sandvold, ML, 2010
)
0.36
" Food components and dosing time significantly altered the oral pharmacokinetics of nifedipine in rats, implying that the altered bioavailability and higher plasma concentrations in the morning time may influence dosing regimens of nifedipine for hypertension patients."( Effect of food components and dosing times on the oral pharmacokinetics of nifedipine in rats.
Cao, QR; Cui, JH; Han, HK; Lee, BJ; Lee, J; Oh, KT; Park, I; Park, JB, 2010
)
0.36
" However, flavonoid bioavailability is often poor probably due to their interaction with plasma proteins."( Flavonoid binding to human serum albumin.
Ascenzi, P; Bolli, A; Fanali, G; Fasano, M; Marino, M; Rimbach, G, 2010
)
0.36
" The apparent absorption rate of fat was significantly lower in the BOO group than in the SO group."( Structured triacylglycerol containing behenic and oleic acids suppresses triacylglycerol absorption and prevents obesity in rats.
Arishima, T; Hirotsuka, M; Ikeda, I; Izumisawa, A; Kohno, M; Kojima, M; Sagi, N; Seino, S; Tachibana, N; Takamatsu, K; Yamahira, T, 2010
)
0.36
"A nonoral alternative such as transdermal system is desired to improve bioavailability and to maintain a constant and prolonged drug level with reduced frequency of dosing."( Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling.
Bindhani, A; Mallick, S; Pattnaik, S; Swain, K, 2011
)
0.37
"Dipyridamole shows poor and variable bioavailability after oral administration due to pHdependent solubility, low biomembrane permeability as well as being a substrate of P-glycoprotein."( Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation.
Guo, F; He, J; Liu, F; Liu, M; Xie, B; Xu, C; Xu, H; Zhong, H, 2011
)
0.37
" In this work, novel FEX loaded water in oil microemulsion (w/o) was designed to improve bioavailability and compared with Fexofen(®) syrup in in vitro and in vivo studies."( Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies.
Alvarez, IG; Gundogdu, E; Karasulu, E, 2011
)
0.37
"6-fold compared with that of the commercially available ligustrazine injection (LI), suggesting enhanced bioavailability from the lipid-based emulsion."( Development of ligustrazine-loaded lipid emulsion: formulation optimization, characterization and biodistribution.
Kim, JO; Li, G; Marasini, N; Quan, Q; Wei, L; Yong, CS, 2012
)
0.38
" The dissolution behaviors and in vivo bioavailability of controlled release matrix tablet in healthy human volunteers were investigated."( Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion.
Lee, BJ; Lim, J; Oh, KT; Park, JB; Piao, ZZ; Rhee, YS; Tran, PH; Tran, TT; Vo, TV, 2013
)
0.39
" Contrary to accepted dogma, stearic acid was well absorbed and less than 10% was desaturation to oleic acid."( Human studies using isotope labeled fatty acids: answered and unanswered questions.
Emken, E, 2013
)
0.39
"Buspirone HCl has very low oral bioavailability (4%) due to deactivation by extensive first pass effect."( Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.
Elsayed, I; Shamma, RN, 2013
)
0.39
" The oral bioavailability of lipophilic compounds can be enhanced by promoting their intestinal lymphatic transport through co-administration with digestible lipids."( Enhanced lymphatic transport of bioactive lipids: cell culture study of polymethoxyflavone incorporation into chylomicrons.
Chen, J; McClements, DJ; Song, M; Xiao, H; Yao, M; Zheng, J, 2013
)
0.39
" Oral bioavailability of T-OA microemulsion and oleic acid solution were checked by using rat model."( In-vitro and in-vivo comparison of T-OA microemulsions and solid dispersions based on EPDC.
Cai, Z; Cao, S; Hou, P; Lei, H; Liu, J; Liu, Y; Ni, J; Wang, P; Wang, Y; Zhang, T, 2015
)
0.42
"Low bioavailability of rifampicin, one of the main antituberculous drug, stimulates searches of its new optimized formulations."( [Drug delivery system on the base of phospholipid nanoparticles for rifampicin].
Ipatova, OM; Medvedeva, NV; Prozorovskiĭ, VN; Sanzhakov, MA; Tarkhovskaia, TI; Tikhonova, EG,
)
0.13
" However, the oral bioavailability of these methoxyflavones has been shown to be low."( Transdermal permeation of Kaempferia parviflora methoxyflavones from isopropyl myristate-based vehicles.
Jaipakdee, N; Limpongsa, E; Sripanidkulchai, B; Tuntiyasawasdikul, S, 2014
)
0.4
"2-fold improved oral bioavailability of leuprolide oleate SMEDDS compared to a leuprolide acetate control solution."( In vivo evaluation of an oral self-microemulsifying drug delivery system (SMEDDS) for leuprorelin.
Bernkop-Schnürch, A; Hauptstein, S; Hintzen, F; Laffleur, F; Müller, C; Perera, G, 2014
)
0.4
" This paper aimed to explore the performance of polymeric mixed micelles on solubilization, stabilization and bioavailability enhancement with stiripentol as model drug."( Exploring the potential of self-assembled mixed micelles in enhancing the stability and oral bioavailability of an acid-labile drug.
Wang, H; Wu, B; Zhang, T; Zhang, X; Zhou, X, 2014
)
0.4
" The microencapsulation by complex coacervation was shown to be a technique that favors the bioavailability and preservation of bioactive components of the bocaiuva oil."( Diuretic and Anti-Inflammatory Activities of the Microencapsulated Acrocomia aculeata (Arecaceae) Oil on Wistar Rats.
Iwamoto, RD; Kassuya, CA; Lescano, CH; Sanjinez-Argandoña, EJ, 2015
)
0.42
" In this context, NO generation from the nitrate-nitrite-NO pathway mostly derived from green leafy vegetables appears to be an alternative source for NOS-dependent NO production, ensuring NO bioavailability also in situations when the endogenous 1-arginine/NO synthase pathway is dysfunctional or physiologically reduced in local hypoxic conditions."( Vascular effects of the Mediterranean diet part I: anti-hypertensive and anti-thrombotic effects.
Capurso, A; Capurso, C; Massaro, M; Scoditti, E; Vendemiale, G, 2014
)
0.4
"Curcumin is a potent natural anticancer agent, but its effectiveness is limited by properties such as very low solubility, high rate of degradation, and low rate of absorption of its hydrophobic molecules in vivo."( A novel diblock of copolymer of (monomethoxy poly [ethylene glycol]-oleate) with a small hydrophobic fraction to make stable micelles/polymersomes for curcumin delivery to cancer cells.
Erfani-Moghadam, V; Najafi, F; Nomani, A; Sadeghizadeh, M; Yazdani, Y; Zamani, M, 2014
)
0.4
"The solubility of starch-inclusion complexes affects the digestibility and bioavailability of the included molecules."( Effects of chemical and enzymatic modifications on starch-oleic acid complex formation.
Arijaje, EO; Wang, YJ, 2015
)
0.42
"Poor water solubility of a drug is a major challenge in drug delivery research and a main cause for limited bioavailability and pharmacokinetic parameters."( Custom fractional factorial designs to develop atorvastatin self-nanoemulsifying and nanosuspension delivery systems--enhancement of oral bioavailability.
Ahmed, OA; Al-Sawahli, MM; Hashem, FM; Nasr, M, 2015
)
0.42
"The current research work explores the potential applications of cationic self-nanoemulsifying oily formulations (CSNEOFs) for enhancing the oral bioavailability of olmesartan medoxomil."( Positively charged self-nanoemulsifying oily formulations of olmesartan medoxomil: Systematic development, in vitro, ex vivo and in vivo evaluation.
Beg, S; Jain, S; Katare, OP; Sharma, G; Singh, B; Thanki, K, 2015
)
0.42
" The in situ single-pass perfusion and oral bioavailability studies were performed in rats."( Oleic acid derivative of polyethylenimine-functionalized proliposomes for enhancing oral bioavailability of extract of Ginkgo biloba.
Bi, Y; Du, L; Fan, C; Lee, RJ; Teng, L; Xie, J; Yang, S; Zhao, L; Zheng, B, 2016
)
0.43
"The aim of the present study was to prepare sublingual delivery systems for sildenafil and evaluate its relative bioavailability after sublingual administration in rabbits to attain a rapid onset of action with good efficacy at lower doses."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.43
"The purpose of this study was to prepare Brucea javanica oil cationic nanoemulsions (BJO-CN) with BJO as drug as well as oil phase and chitosan as cationic inducer, to explore the practical suitability of using cationic nanoemulsions for oral delivery of mixed oil, and to test its bioavailability and antitumor effect."( Preparation, characterization, and evaluation of antitumor effect of Brucea javanica oil cationic nanoemulsions.
Dai, W; Liu, TT; Liu, XY; Mu, LQ; Wang, CB; Xiang, DX, 2016
)
0.43
"The main purpose of this research was to design a self-nanoemulsifying drug delivery system (SNEDDS) for improving the bioavailability of cyclovirobuxine D as a poorly water-soluble drug."( Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D.
Hou, X; Jia, XB; Ke, Z, 2016
)
0.43
" The relative bioavailability of SNEDDS was 200."( Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D.
Hou, X; Jia, XB; Ke, Z, 2016
)
0.43
"To improve the solubility, dissolution and intestinal permeation thereby bioavailability of risperidone through a novel self-nanoemulsifying powder (SNEP) formulations."( Enhanced oral delivery of risperidone through a novel self-nanoemulsifying powder (SNEP) formulations: in-vitro and ex-vivo assessment.
Bakshi, V; Bandi, S; Sanka, K, 2016
)
0.43
" The potential benefits are, however, limited due to its poor water solubility and rapid degradation which result in low bioavailability on administration."( Curcumin-loaded nanoliposomes linked to homing peptides for integrin targeting and neuropilin-1-mediated internalization.
Balalaie, S; Haririan, I; Kangarlou, S; Ramezanpour, S; Roudbar Mohammadi, S, 2017
)
0.46
"Oral bioavailability of flavonoids (and many phenolic drugs) is severely limited by extensive first-pass glucuronidation."( Sodium Oleate-Based Nanoemulsion Enhances Oral Absorption of Chrysin through Inhibition of UGT-Mediated Metabolism.
Dong, D; Li, Z; Quan, E; Wu, B; Xie, Q; Yuan, X, 2017
)
0.46
" The in vivo pharmacokinetic study gave many folds increase in oral bioavailability than CC suspension, which was further confirmed by antihypertensive activity in a murine model."( Formulation and Optimization of Candesartan Cilexetil Nano Lipid Carrier: In Vitro and In Vivo Evaluation.
Ahmad, FJ; Ali, A; Fazil, M; Hafeez, A; Imam, SS; Khan, S; Paudel, A, 2017
)
0.46
"As the buccal route of administration has the ability to avoid the GI tract and first-pass effect by directing the absorption toward the cheek area, the bioavailability of BCS class III drugs can be increased through this route."( Bioadhesive Drug Delivery System for Enhancing the Permeability of a BCS Class III Drug via Hot-Melt Extrusion Technology.
Kim, DW; Martin, ST; Mendonsa, NS; Repka, MA; Thipsay, P, 2017
)
0.46
" The OA bearing hexagonal LCNDs provided a significant enhancement in the intestinal permeation compared to glyceryl monooleate cubical nanodispersion and demonstrated an outstanding in vivo performance by maintaining higher ROS plasma levels up to 8 h and enhancing oral bioavailability compared to commercial tablet."( Hexagonal Liquid Crystalline Nanodispersions Proven Superiority for Enhanced Oral Delivery of Rosuvastatin: In Vitro Characterization and In Vivo Pharmacokinetic Study.
Gabr, MM; Mortada, SM; Sallam, MA, 2017
)
0.46
"Present investigation deals with formulation and evaluation of tamoxifen (TMX)-loaded liquid crystalline nanoparticles (TMX-LCNPs) for improving oral bioavailability and safety of the existing treatment."( Improved Oral Bioavailability, Therapeutic Efficacy, and Reduced Toxicity of Tamoxifen-Loaded Liquid Crystalline Nanoparticles.
Heeralal, B; Jain, S; Kushwah, V; Swami, R; Swarnakar, NK, 2018
)
0.48
"The purpose of the current study is to develop nanostructured lipid carriers (NLCs) for the delivery of the antihyperlipidemic drug simvastatin (SIM) to increase its extremely low oral bioavailability (<5%) and prolong its antihyperlipidemic effect."( Nanostructured lipid carriers for improved oral delivery and prolonged antihyperlipidemic effect of simvastatin.
Allam, A; El-Badry, M; Elsabahy, M; Fathi, HA; Fetih, G, 2018
)
0.48
"The bioavailability of ivermectin is modulated by lipid-based formulations and membrane efflux transporters such as Breast Cancer Resistance Protein and P-glycoprotein (BCRP and P-gp)."( Oleic acid increases uptake and decreases the P-gp-mediated efflux of the veterinary anthelmintic Ivermectin.
Houshaymi, B; Kedees, M; Nasreddine, N; Soayfane, Z, 2019
)
0.51
"The formulation of the antituberculosis drug rifampicin embedded into 20-30 nm nanoparticles from soy phosphatidylcholine and sodium oleate, is characterized by greater bioavailability as compared with free drug substance."( [Increase of antituberculosis efficiency of rifampicin embedded into phospholipid nanoparticles with sodium oleate].
Ipatova, OM; Medvedeva, NV; Prozorovskiy, VN; Sanzhakov, MA; Tikhonova, EG; Torkhovskaya, TI; Zakharova, TS, 2018
)
0.48
" In conclusion, mucoadhesive olaminosomes succeeded in enhancing agomelatine bioavailability in rabbits' eyes confirming the development of a novel ocular nanocarrier for insoluble drugs."( Mucoadhesive olaminosomes: A novel prolonged release nanocarrier of agomelatine for the treatment of ocular hypertension.
Abd-Elsalam, WH; ElKasabgy, NA, 2019
)
0.51
" Overall, results revealed the capability of ufosomes in improving the skin bioavailability of clotrimazole."( Clotrimazole Loaded Ufosomes for Topical Delivery: Formulation Development and In-Vitro Studies.
Bolla, PK; Deaguero, I; Meraz, CA; Renukuntla, J; Rodriguez, VA; Singh, M; Yellepeddi, VK, 2019
)
0.51
" The two systems were loaded with resveratrol (RSV), a hydrophobic polyphenol endowed with anti-cancerogenic, anti-inflammatory, and heart/brain protective effects, but with low bioavailability mainly due to poor aqueous solubility."( Chitosan Oleate Coated Poly Lactic-Glycolic Acid (PLGA) Nanoparticles versus Chitosan Oleate Self-Assembled Polymeric Micelles, Loaded with Resveratrol.
Bonferoni, MC; Catenacci, L; Dacarro, G; Ferrari, F; Malavasi, L; Miele, D; Rossi, S; Sandri, G; Sorrenti, M, 2019
)
0.51
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
"A nanoemulsion system was designed for Atorvastatin calcium (ATOR) transdermal delivery to overcome its poor bioavailability of (30%) resulting from the extensive first-pass effect and dissolution rate-limited in vivo absorption."( Boosting transdermal delivery of atorvastatin calcium via o/w nanoemulsifying system: Two-step optimization, ex vivo and in vivo evaluation.
Elhuoni, MA; Ghoneim, AM; Ishak, RAH; Shaker, DS, 2020
)
0.56
" However, low aqueous solubility and bioavailability limit its clinical application."( Chitosan-oleic acid-sodium alginate a hybrid nanocarrier as an efficient delivery system for enhancement of lutein stability and bioavailability.
Jayapala, N; Toragall, V; Vallikannan, B, 2020
)
0.56
" Bioavailability results showed a sustained release profile was achieved following the oral formulation administration."( Oral Delivery of Teriparatide Using a Nanoemulsion System: Design, in Vitro and in Vivo Evaluation.
Alkhamis, K; Almaaytah, AM; Altaani, BM; Dadou, S; Daradka, MH; Hananeh, W, 2020
)
0.56
" However, clinical application of AMPs is associated with poor bioavailability and toxicity."( Biomimetic amphiphilic chitosan nanoparticles: Synthesis, characterization and antimicrobial activity.
Ahmad, N; Azmi, F; Wai, LK; Wee, CE; Zin, NM, 2021
)
0.62
" Previous studies have shown that natural sesame oil promotes the intestinal lymphatic transport and oral bioavailability of the highly lipophilic drug cannabidiol (CBD)."( Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol.
Barrett, DA; Berton, M; Bettonte, S; Chu, Y; Constantinescu, CS; Feng, W; Fischer, PM; Gershkovich, P; Lee, JB; Qin, C; Stocks, MJ; Zgair, A, 2021
)
0.62
"Candesartan cilexetil (CC), a prodrug of candesartan (CDT), is a class II BCS drug that suffers from poor oral bioavailability because of low aqueous solubility, P-gp efflux and first-pass metabolism."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
" The synergistic combination of Peceol™ and Span™ 60 probably surmounted the P-gp efflux with an increase in oral absolute bioavailability of niosomes to five times that of CC suspension."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
"The new niosomal formulations of CC containing Peceol™ with Span™ 60 and cholesterol either uncoated or coated with chitosan were a successful paradigm in achieving high oral absolute bioavailability and increased Caco-2 cells biocompatibility."( New Peceol™/Span™ 60 Niosomes Coated with Chitosan for Candesartan Cilexetil: Perspective Increase in Absolute Bioavailability in Rats.
AbuElfadl, A; Boughdady, M; Meshali, M, 2021
)
0.62
" Oleic acid-embedded cellulose acetate membranes (OECAMs) were developed to evaluate the bioavailability of epoxiconazole (EPO) to earthworms (Eisenia fetida)."( Accumulation of epoxiconazole from soil via oleic acid-embedded cellulose acetate membranes and bioavailability evaluation in earthworms (Eisenia fetida).
Chen, Y; Dong, F; Liu, X; Wu, X; Xu, J; Yuan, S; Zheng, Y, 2022
)
0.72
"The aim of the study was to improve the bioavailability of Cinacalcet hydrochloride (CLC) and enhance its efficacy by the nanoemulsion drug delivery system."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
0.72
" The release of CLC-NE in vitro was investigated with four different dissolution media, and the bioavailability of CLC-NE in vivo was studied through beagle dogs."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
0.72
" CLC-NE has similar dissolution rates in different pH media, and the relative bioavailability of CLC-NE was 166."( Cinacalcet hydrochloride-nanoemulsion: preparation, characterization, enhanced bioavailability and pharmacodynamics.
Chen, GG; Ren, LL; Wang, J, 2022
)
0.72
" The efficacy of conventional CRC chemotherapy is hampered by poor drug solubility and bioavailability and suboptimal pharmacokinetic profiles."( Oral delivery of camptothecin-loaded multifunctional chitosan-based micelles is effective in reduce colorectal cancer.
Almeida, A; Castro, F; Lúcio, M; Resende, C; Sarmento, B; Schwartz, S, 2022
)
0.72
"The simultaneous improvement of quercetin (QUE) processing stability and bioavailability has always presented a technical challenge during food processing."( Improving effect of oleic acid-mediated sodium caseinate-based encapsulation in an ultrasound field on the thermal stability and bioaccessibility of quercetin.
Guo, Z; Li, J; Liu, Y; Wang, S, 2022
)
0.72
" The mechanism involved could be the contribution of T80 to increase the solubilization of FA (and possibly other products of the lipolysis) in the duodenal medium, consequently affecting the potential bioavailability of fatty acids."( Solubilization of lipolysis products in mixed micelles is enhanced in presence of bile salts and Tween 80 as revealed by a model study (oleic acid) and emulsified chia-oil.
Bellesi, FA; M R Pilosof, A; Naso, JN; Pizones Ruiz-Henestrosa, VM, 2022
)
0.72
" However, their use is restricted by their poor bioavailability and high risk-benefit ratio."( Nanostructured Lipid Carriers for Oral Delivery of a Corticosteroid: Role of Formulation on Biopharmaceutical Performance.
Ibrahim, SS, 2023
)
0.91
" However, the use of HTyr as a therapeutic agent for clinical applications is limited by its low bioavailability and rapid excretion in humans."( In Vitro Anti-Proliferative and Apoptotic Effects of Hydroxytyrosyl Oleate on SH-SY5Y Human Neuroblastoma Cells.
Bernini, R; Cicaloni, V; Clemente, M; Laghezza Masci, V; Ovidi, E; Salvini, L; Taddei, AR; Tiezzi, A; Tinti, L; Villanova, N, 2022
)
0.72
" However, extremely low absorption rate of olive phenolic compounds restricts their bioactivity."( Hydroxytyrosol oleate: A promising neuroprotective nanocarrier delivery system of oleuropein and derivatives.
Brocchini, S; Nardi, M; Procopio, A; Somavarapu, S, 2023
)
0.91
" At the same time, we found that stearic acid was not only poorly absorbed by itself in the small intestine but also reduced the entire absorption system of the small intestine."( Diet containing stearic acid increased food intake in mice by reducing serum leptin compared with oleic acid.
Chen, L; Feng, X; Gao, P; Jiang, Q; Li, Y; Liang, J; Mo, Y; Shu, G; Sun, Z; Wang, L; Wang, S; Wu, X; Xie, K; Zhu, C; Zhu, S; Zhu, X, 2023
)
0.91
" This study suggests that mucoadhesive buccal tablets containing self-assembled LON may effectively increase the medication adherence for pediatric and geriatric patients by improving the bioavailability and permeation rate of LEU."( Mucoadhesive buccal tablet of leuprolide and its fatty acid conjugate: Design, in vitro evaluation and formulation strategies.
Jin, H; Lee, BJ; Ngo, HV; Park, C, 2023
)
0.91
"Passive sampling technology is widely used to evaluate the bioavailability of pollutants."( Bioavailability assessment of difenoconazole to earthworms (Eisenia fetida) in soil by oleic acid-embedded cellulose acetate membrane.
Chen, Y; Feng, X; Liu, X; Mao, L; Zhang, L; Zheng, Y; Zhu, L, 2023
)
0.91

Dosage Studied

Oleic acid is a pharmaceutical excipient and has been widely used in many dosage forms. The newly synthesized linoleic acid derivative, FR236924, induces a long-lasting facilitation of hippocampal neurotransmission.

ExcerptRelevanceReference
" Absorption of neutral lipids decreased with increasing quantities of resin, and with the highest dosage (14% wt/wt) less than 30% of dietary lipids were assimilated."( Bile is essential for lipid assimilation in Leach's storm petrel, Oceanodroma leucorhoa.
Place, AR, 1992
)
0.28
" Oleic acid killing of cells grown in carotenoid expression medium was determined as the dosage of oleic acid in 2 M NaCl-2 mM EDTA that would kill 20% of the cells in 60 min at 37 degrees C (i."( Correlation of carotenoid production, decreased membrane fluidity, and resistance to oleic acid killing in Staphylococcus aureus 18Z.
Boardman, JL; Chamberlain, NR; Kapral, FA; Mehrtens, BG; Rearick, JI; Xiong, Z, 1991
)
0.28
" The pancreatic bicarbonate and volume outputs correlated with the dosage of HCl administered and with the elevations in plasma secretin concentrations."( Characterization of secretin release in response to food and intraduodenal administration of fat and hydrochloric acid.
Draviam, EJ; Gomez, G; Greeley, GH; Hashimoto, T; Hill, FL; Miyashita, T; Singh, P; Thompson, JC; Uchida, T, 1991
)
0.28
"Bilateral ovariectomy carried out in Java macaques with simultaneous dosed ligation of common bile duct distally to duodenum in order to induce acalculous hepato-cholecystitis, does not alter the lithogenic index of the bile."( [Effects of ovariectomy on the composition of fatty acids of phospholipids in Java macaques with cholestasis].
Bogdarin, IuA; Goncharov, NP, 1990
)
0.28
" The hourly 14CO2 production was measured for 12 h for estimating the oxidation rate of dosed triacylglycerols."( Limits of medium-chain and long-chain triacylglycerol utilization by neonatal piglets.
Chiang, SH; Clarke, SD; Cornelius, SG; Pettigrew, JE, 1990
)
0.28
"The present study was an attempt to develop a new dosage form of cinnarizine, which is slightly soluble in water, using lipid as a vehicle."( Enhancement of the oral bioavailability of cinnarizine in oleic acid in beagle dogs.
Kayano, M; Machida, Y; Nagai, T; Tatsuishi, K; Tokumura, T; Tsushima, Y, 1987
)
0.27
" The cholesterol removal and all the agents used induced dose-response decreases in membrane lipid order as measured by fluorescence polarization or ESR."( The effects of membrane lipid order and cholesterol on the internal and external cationic sites of the Na+-K+ pump in erythrocytes.
Bruckdorfer, KR; Chailley, B; Claret, M; Giraud, F, 1981
)
0.26
" Repeat dosing produced index values with standard deviations less than the group sample standard deviations."( Single isotope evaluation of pulmonary capillary protein leak (ARDS model) using computerized gamma scintigraphy.
Beachley, MC; Greenfield, LJ; Hirsch, JI; Strash, AM; Sugerman, HJ; Tatum, JL,
)
0.13
"To improve the limited oral bioavailability of sulpiride, a dosage form containing sodium oleate as an absorption enhancer was developed and evaluated using gastric-emptying-controlled rabbits in a cross-over manner."( Improving the oral bioavailability of sulpiride by sodium oleate in rabbits.
Iseki, K; Kohri, N; Miyazaki, K; Naasani, I, 1995
)
0.29
" The experimental results showed that CVF, given 20 h before the dosage depleting complements exceed 95%, significantly attenuated oleic acid-induced pulmonary dysfunction, including hypoxemia, increasing veno-arterial shunt and P(A-a)O2 and decreasing dynamic compliance and pulmonary blood flow."( Protective effect of cobra venom factor on pulmonary injury induced by oleic acid.
Huang, SJ; Ren, XD; Sun, JJ; Zhu, ZG, 1994
)
0.29
" Animals were then divided into three groups: (1) gas ventilation with a tidal volume of 15 ml/kg (control, GV, n = 5); (2) partial liquid ventilation at a gas tidal volume of 15 ml/kg with 10 ml/kg incremental pulmonary dosage of perflubron from 10 to 50 ml/kg (best fill, BF, n = 6); (3) administration of 35 ml/kg perflubron pulmonary dose with 5 ml/kg incremental increase in gas tidal volume from 10 to 30 ml/kg (best tidal volume, BTV, n = 5)."( Oxygen dynamics during partial liquid ventilation in a sheep model of severe respiratory failure.
Hirschl, RB; Overbeck, MC; Parent, AC, 1997
)
0.3
" Female Sprague-Dawley rats were dosed with diethylnitrosamine (15 mg/kg) at 24 h of age."( Effect of dietary lipid on gamma-glutamyl transferase-positive foci during hepatocarcinogenesis in rats.
Chen, HW; Ko, JJ; Lii, CK, 1998
)
0.3
" One set of tablets was dosed with the capsule and the other one hour later."( The effect of oleic acid on the human ileal brake and its implications for small intestinal transit of tablet formulations.
Chauhan, S; Davis, SS; Dobson, CL; Sparrow, RA; Wilding, IR, 1999
)
0.3
" The o/w emulsion of tacrolimus may be an improved dosage form via the enteral route."( Pharmacokinetic advantages of a newly developed tacrolimus oil-in-water-type emulsion via the enteral route.
Hashimoto, H; Kazui, T; Muhammad, BA; Suzuki, K; Suzuki, Y; Uno, T, 1999
)
0.3
" Animals were dosed 100 mg/kg capsaicin after the administration of olive oil, and the bile was obtained for 6 hours continuously after dosing with capsaicin for analysis of FFAs using HPLC methods."( Effects of capsaicin on biliary free fatty acids in rats.
Hori, Y; Nakamura, K; Saito, A; Yamamoto, M, 2000
)
0.31
"Various monoolein-water systems containing tramadol HCl, a potent analgesic, were formulated to obtain sustained-release dosage forms which could be administered by subcutaneous, intramuscular or intrathecal injections."( In vitro/in vivo characterization of a tramadol HCl depot system composed of monoolein and water.
Fontaine, J; Malonne, H; Moës, A, 2000
)
0.31
"28) %, in the rings from SHR rats treated with OO, and were more pronounced than in WKY rats In the same way, OO attenuated the dose-response curves induced by phenylephrine (10(-8)-10(-5) m) from SHR rats, accompanied with a slower contraction."( Effects of dietary oleic-rich oils (virgin olive and high-oleic-acid sunflower) on vascular reactivity in Wistar-Kyoto and spontaneously hypertensive rats.
Herrera, MD; Marhuenda, E; Pérez-Guerrero, C; Ruiz-Gutiérrez, V, 2001
)
0.31
"SV2 cells; kinetics and dose-response studies established that maximal MCAD gene stimulation was reached 4 h after addition of 50 microM oleate (C18:1) in the culture medium."( Effects of fatty acids on mitochondrial beta-oxidation enzyme gene expression in renal cell lines.
Bastin, J; Djouadi, F; Ouali, F, 2002
)
0.31
" Atenolol was either dosed separately or incorporated into one of the capsules."( The effect of ileal brake activators on the oral bioavailability of atenolol in man.
Chauhan, S; Davis, SS; Dobson, CL; Sparrow, RA; Wilding, IR, 2002
)
0.31
"The newly synthesized linoleic acid derivative, FR236924, induces a long-lasting facilitation of hippocampal neurotransmission based on a persistent enhancement in the activity of presynaptic nicotinic ACh receptors via a PKC pathway and the ensuing increase in glutamate release, not only in vitro but in vivo at a low dosage (2mg/kg, ip), which suggested the possibility of its use as a promising anti-dementia drug."( The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
Nishizaki, T; Tanaka, A, 2003
)
0.32
"The rabbits were randomly divided into 11 groups: oleic acid group; control group; treatment groups including low, middle and high dosage groups of Qingkailing and MP alone and combined, respectively."( [Therapeutic effect of Qingkailing and methylprednisolone injection alone or combined on the acute lung injury induced by oleic acid in rabbits].
Cui, HF; Du, GY; Gao, SR; Gao, W; He, R; Hui, LQ; Liang, RX; Wang, XR; Wu, ZL; Zhang, CY; Zhao, Y; Zhu, XX, 2005
)
0.33
"The rabbits were randomly divided into 11 groups: oleic acid group; control group; treatment groups including low, middle and high dosage groups of Qingkailing and Shengmai injection alone and combined, respectively."( [Therapeutic effect of qingkailing and shengmai injection alone or combined on the acute lung injury induced by oleic acid in rabbits].
Cui, HF; Du, GY; Gao, SR; Gao, W; He, R; Hui, LQ; Lang, RX; Wang, XR; Wu, ZL; Zhang, CY; Zhao, Y; Zhu, XX, 2005
)
0.33
" The magnetite entrapment efficiency and magnetite content were assessed by dosing iron in the composite nanoparticles."( Development and characterization of sub-micron poly(D,L-lactide-co-glycolide) particles loaded with magnetite/maghemite nanoparticles.
Chourpa, I; Cohen-Jonathan, S; Douziech-Eyrolles, L; Dubois, P; Marchais, H; Ngaboni Okassa, L; Soucé, M, 2005
)
0.33
" Dosing continuous cultures of mixed ruminal microorganisms with 1-(13C)-oleic acid increased the 13C enrichment of both HSA and KSA at 24 h postdosing, and showed that the majority (96 and 85%, respectively) of the HSA and KSA present in the 24-h samples originated from oleic acid."( The production of 10-hydroxystearic and 10-ketostearic acids is an alternative route of oleic acid transformation by the ruminal microbiota in cattle.
Abughazaleh, AA; Freeman, S; Jenkins, TC; Thies, EJ, 2006
)
0.33
" Arterial blood gases and reduced breath rates respiratory rate were not improved in other PPS treatment groups but 4 hours-survival rate was lowered, lung index was decreased, protein content s in BALF and TNF-alpha level in serum were lowered, and pathological changes were ameliorated compared with group given saline after OA, especially in high dosage of PPS (150-200 mg/kg) group (P<0."( [Influence of different doses of porcine pulmonary on the therapeutic effects in rats with oleic acid induced acute lung injury].
Huang, JX; Lu, J; Sun, Y; Wang, YQ; Zhong, JG, 2006
)
0.33
"Film forming polymeric solutions may present an alternative to the common transdermal dosage forms such as patches or gels."( Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs.
Franke, P; Lehr, CM; Schaefer, UF; Zurdo Schroeder, I, 2007
)
0.34
" The purpose of this study was to evaluate if the use of a 5% oleic acid emulsion previous to the phototherapy sessions was useful in reducing the total dosage necessary for whitening in patients with psoriasis."( Optimization of narrow-band uvb with a 5% oleic acid cream in the treatment of psoriasis.
Martín-Ezquerra, G; Sánchez-Regaña, M; Umbert-Millet, P, 2007
)
0.34
" We have examined the inhibitory effect of free fatty acid (FFA), a binding inhibitor for site II of HSA, on the binding of flurbiprofen in-vitro and in-vivo by ultrafiltration, to establish an effective dosage of FP-ax."( Dosage plan of a flurbiprofen injection product using inhibition of protein binding by lipid emulsion in rats.
Arimori, K; Higuchi, S; Kawai, K; Ogata, K; Takamura, N; Tokunaga, J, 2008
)
0.35
" cruzi PKC in a dose-response way."( Involvement of protein kinase C isoenzymes in Trypanosoma cruzi metacyclogenesis induced by oleic acid.
Belaunzarán, ML; de Isola, EL; Giménez, G; Lammel, EM; Wainszelbaum, MJ, 2009
)
0.35
" The formulation was optimized for skin permeation enhancers, pH of the system, and dosage strength using in vitro and in vivo techniques."( Ketorolac tromethamine transdermal gel: development, in vitro and in vivo evaluation.
Bommagani, M; Dubey, R; Karnati, HR; Menon, VC; Mullangi, R; Thammera, RK; Venkateswarlu, V, 2009
)
0.35
" This information on melatonin absorption behaviors and its modulation by pharmaceutical excipients can be used in further oral dosage formulations to affect circadian rhythm."( New findings on melatonin absorption and alterations by pharmaceutical excipients using the Ussing chamber technique with mounted rat gastrointestinal segments.
Lee, BJ; Tran, HT; Tran, PH, 2009
)
0.35
" The effects of operating variables including the mole ratio of oleic acid to monoacid TAG, temperature, enzyme dosage and reaction time on incorporation were also investigated."( Fatty acid selectivity of lipases during acidolysis reaction between oleic acid and monoacid triacylglycerols.
Durmaz, G; Hayaloglu, AA; Karabulut, I, 2009
)
0.35
"The development of a controlled-release dosage form of zidovudine (AZT) is of crucial importance, in view of the pharmacokinetics of its toxic activity."( Development and in vitro evaluation of surfactant systems for controlled release of zidovudine.
Barbi, MS; Carvalho, FC; Chiavacci, LA; Gremião, MP; Sarmento, VH, 2010
)
0.36
"A semisolid dosage form of clonazepam (CZP), administered to the oral cavity between the lower gum and bottom lip with small volume of saline, was developed to obtain the stable dosage which can replace the injection dosage form."( [Development of semisolid dosage form of clonazepam for oral cavity administration].
Machida, Y; Onishi, H; Sakata, O, 2010
)
0.36
"The present study was aimed to investigate the effect of food components and dosing time on the oral exposure of nifedipine in rats."( Effect of food components and dosing times on the oral pharmacokinetics of nifedipine in rats.
Cao, QR; Cui, JH; Han, HK; Lee, BJ; Lee, J; Oh, KT; Park, I; Park, JB, 2010
)
0.36
" Novelty of the work: A transdermal delivery of non-steroidal antinflammatory drugs like lumiracoxib (LM) can be an interesting alternative to the oral route of this drug, since it was recently withdraw of the market due to the liver damage when systemically administered in tablets as dosage form."( Influence of oleic acid on the rheology and in vitro release of lumiracoxib from poloxamer gels.
de Sousa, VP; Moreira, TS; Pierre, MB, 2010
)
0.36
") dosage form of clonazepam (CZ), an oral droplet formulation of CZ was developed previously; however, the droplet was physically unstable."( Semi-solid dosage form of clonazepam for rapid oral mucosal absorption.
Machida, Y; Onishi, H; Sakata, O, 2011
)
0.37
"A semi-solid dosage form, composed of polyethylene glycol 1500 (PEG), CZ, and oleic acid (OA) at 37/1/2 (w/w) and named PEG/CZ/OA, and a semi-solid dosage form containing PEG and CZ at 39/1 (w/w), called PEG/CZ, were prepared."( Semi-solid dosage form of clonazepam for rapid oral mucosal absorption.
Machida, Y; Onishi, H; Sakata, O, 2011
)
0.37
"The semi-solid dosage forms were much more stable physically than the droplet, that is, no recrystallization of CZ was observed for at least 8 days."( Semi-solid dosage form of clonazepam for rapid oral mucosal absorption.
Machida, Y; Onishi, H; Sakata, O, 2011
)
0.37
" We studied the effects of dosing route and tracer concentration on the mass isotopomer distribution profile as well as the action of selective inhibitors of microsomal tri-glyceride transfer protein (MTP) in mice and diacylglycerol acyltransferase 1 (DGAT1) in nonhuman primates, using a stable-isotopically labeled approach."( The use of stable-isotopically labeled oleic acid to interrogate lipid assembly in vivo: assessing pharmacological effects in preclinical species.
Balkovec, JM; Bhat, G; Castro-Perez, JM; Chen, D; DeVita, RJ; Gagen, K; He, T; Herath, K; Hubbard, BK; Imbriglio, J; Johns, DG; Liu, J; Marsh, DJ; McLaren, DG; Mendoza, V; Miller, PL; Pinto, S; Previs, SF; Roddy, TP; Rosa, R; Strack, A; Stribling, S; Taggart, A; Wang, SP, 2011
)
0.37
"Our study suggests that optimized DNR-MNPs formulation possesses sustained drug-release and favorable antitumor properties, which may be used as a conventional dosage form for antitumor therapy."( Synthesis and antitumor efficacy of daunorubicin-loaded magnetic nanoparticles.
Cai, X; Chen, B; Chen, J; Chen, P; Liu, R; Wang, J; Wang, X; Xia, G; Zhang, Y, 2011
)
0.37
" Essentially, animals are dosed with an exogenous deuterated tracer (d7-stearic acid) as substrate, and the converted d7-oleic acid product is measured to monitor SCD1 inhibition."( Plasma-based approach to measure target engagement for liver-targeting stearoyl-CoA desaturase 1 inhibitors.
Bateman, K; Chan, CC; Huang, Z; Landry, F; Leclair, G; Li, CS; Oballa, R; Zhang, L, 2011
)
0.37
"Response surface methodology (RSM) was used to develop and optimize the mesomorphic phase formulation for a meloxicam transdermal dosage form."( Formulation optimization of transdermal meloxicam potassium-loaded mesomorphic phases containing ethanol, oleic acid and mixture surfactant using the statistical experimental design methodology.
Huang, CT; Huang, YB; Tsai, CH; Tsai, YH; Tsou, HY; Wu, PC, 2011
)
0.37
" The differences in the overall levels of GLA suggest the accumulation of the novel fatty acid was not limited by a lack of incorporation into the triacylgylcerol backbone (>66% GLA achieved), or correlated with gene dosage (GLA levels independent of gene copy number), but rather reflected the differences in Δ6-desaturase activity from the two sources."( High level accumulation of gamma linolenic acid (C18:3Δ6.9,12 cis) in transgenic safflower (Carthamus tinctorius) seeds.
Boothe, JG; Fidantsef, A; Harry, I; Moloney, MM; Nykiforuk, CL; Oinam, GS; Reed, C; Shewmaker, C; Yurchenko, OP; Zaplachinski, S; Zhang, M, 2012
)
0.38
" Compared with the results of our previous single factor experiment, although the values of diolein yield and 1,3-diolien/diolein could not be improved markedly, the enzyme dosage and the reaction medium were spared by 25% and 20%, respectively, which was a remarkable improvement of the enzymatic process."( Rational synthesis of 1,3-diolein by enzymatic esterification.
Du, W; Duan, ZQ; Liu, DH, 2012
)
0.38
" In contrast, incubation of the cells with SB 203580, a specific inhibitor of p38, slightly stimulated ADRP synthesis and induced a proportional dose-response inhibition of PRL-induced β-casein synthesis."( Prolactin and epidermal growth factor stimulate adipophilin synthesis in HC11 mouse mammary epithelial cells via the PI3-kinase/Akt/mTOR pathway.
Chanat, E; Pauloin, A, 2012
)
0.38
" The results suggest that the transdermal application of galantamine drug-in-adhesive patches might be the alternative dosage form to have good efficacy and tolerability for the treatment of Alzheimer disease."( Investigation of formulation factors affecting in vitro and in vivo characteristics of a galantamine transdermal system.
Ha, JM; Kim, JY; Oh, TO; Park, CW; Park, ES; Rhee, YS; Son, DD, 2012
)
0.38
" Mouse models with decreased Npc1 gene dosage are susceptible to weight gain when fed a high-fat diet, but not a low-fat diet, consistent with an Npc1 gene-diet interaction."( The Niemann-Pick C1 gene is downregulated in livers of C57BL/6J mice by dietary fatty acids, but not dietary cholesterol, through feedback inhibition of the SREBP pathway.
Castillo, JJ; Garver, WS; Heidenreich, RA; Jelinek, D; Luo, L; Richardson, LM, 2012
)
0.38
" The effects of different parameters such as pH, desorption solvent, contact time, temperature, ionic strength, and sorbent dosage on the efficiency of magnetic-SPE were investigated."( Application of magnetic nanoparticles to residue analysis of organochlorine pesticides in water samples by GC/MS.
Aydin, ME; Ozcan, S; Tor, A,
)
0.13
" In dose-response studies, unlabeled glucose and OA (20 mM each) inhibited the uptake of their respective radiolabeled counterparts."( Reciprocal inhibition of in vitro substrate movement into avian skeletal muscle.
Braun, EJ; Sweazea, KL, 2013
)
0.39
" A combined method of solid dispersion and controlled release technology could provide versatile dosage formulations containing IDP with poor water solubility and short half-life."( Physical properties and in vivo bioavailability in human volunteers of isradipine using controlled release matrix tablet containing self-emulsifying solid dispersion.
Lee, BJ; Lim, J; Oh, KT; Park, JB; Piao, ZZ; Rhee, YS; Tran, PH; Tran, TT; Vo, TV, 2013
)
0.39
"The aim of this study was to increase the transdermal permeation of buspirone HCl utilizing a stable dosage form."( Transfersomal lyophilized gel of buspirone HCl: formulation, evaluation and statistical optimization.
Elsayed, I; Shamma, RN, 2013
)
0.39
" Therefore, it is important to develop an alternative dosage form which is easier to administer and avoids first-pass metabolism."( Enhanced transdermal drug delivery of zaltoprofen using a novel formulation.
Baek, JS; Cho, CW; Jung, SH; Kang, JS; Lim, JH; Shin, SC, 2013
)
0.39
" The acute study, using a modified OECD 425 progressive dosing procedure, found LD50 values of 59."( Health effects of selected nanoparticles in vivo: liver function and hepatotoxicity following intravenous injection of titanium dioxide and Na-oleate-coated iron oxide nanoparticles in rodents.
Dusinska, M; Handy, RD; Kebis, A; Kucharská, J; Pribojova, J; Staruchova, M; Tulinska, J; Ulicna, O; Volkovova, K, 2015
)
0.42
" The cytotoxicity results demonstrated great advantages of PTX-FA-GON and PTX-GON over the conventional dosage form of pacliaxel (Taxol)."( Novel multifunctional biocompatible gelatin-oleic acid conjugate: self-assembled nanoparticles for drug delivery.
Lee, BJ; Tran, PH; Tran, TT; Vo, CL; Vo, TV, 2013
)
0.39
" The pilot-scale batch reaction was conducted for 8 hours with 5 %w/w enzyme dosage based on the results of TAGs composition of the laboratory-scale interesterified products."( Effectiveness of immobilized lipase Thermomyces lanuginosa in catalyzing interesterification of palm olein in batch reaction.
Saw, MH; Siew, WL, 2014
)
0.4
" The in vivo effects of the nanoparticles were compared with the commercially available Taxol (a solution form of PTX) as a reference dosage form."( Biodistribution and pharmacokinetics in rats and antitumor effect in various types of tumor-bearing mice of novel self-assembled gelatin-oleic acid nanoparticles containing paclitaxel.
Lee, BJ; Tran, PH; Tran, TT, 2014
)
0.4
" This includes energy-restricted weight loss and new findings on the effects of alternative day fasting; novel metabolic and molecular effects of replacing palmitic acid with oleic acid; evidence for a dose-response relationship between the intake of dietary stanols and LDL-C; and identification of a unique metabolic pathway for the excretion of cholesterol."( Nonpharmacological approaches for reducing serum low-density lipoprotein cholesterol.
Griffin, BA, 2014
)
0.4
" Notably, the effects of glycerol application on G3P and 18:1 fatty acid content, and gene expression levels, in cacao leaves were dosage dependent."( Application of glycerol as a foliar spray activates the defence response and enhances disease resistance of Theobroma cacao.
Guiltinan, MJ; Maximova, SN; Smith, P; Zhang, Y, 2015
)
0.42
" The effects of the factors, such as PC concentration, substrate ratio, water amount, lipase dosage and temperature, on the oleic acid content in PC and PC recovery during the interesterification were investigated."( Increase of Oleic Acid Content in Phosphatidylcholine through Lipase-catalyzed Interesterification: Optimization by Response Surface Methodology.
Yang, G; Yang, L, 2015
)
0.42
" Hydroxyurea treated group was on dosage more than 20 mg/kg/day."( Omega 3 (n-3) fatty acids down-regulate nuclear factor-kappa B (NF-κB) gene and blood cell adhesion molecule expression in patients with homozygous sickle cell disease.
Daak, AA; Elbashir, LM; Elbashir, MI; Elderdery, AY; Ghebremeskel, K; Mariniello, K; Mills, J; Scarlett, G, 2015
)
0.42
" Single-step and sequential light-triggered release and retention of the embedded dye molecules are demonstrated, thereby achieving exquisite temporal, spatial, and dosage control of the release, opening up the possibility of using such lipidic biomaterials as effective matrices in therapy, when a continuous release of active drugs might be toxic."( Design of Light-Triggered Lyotropic Liquid Crystal Mesophases and Their Application as Molecular Switches in "On Demand" Release.
Aleandri, S; Landau, EM; Mezzenga, R; Speziale, C, 2015
)
0.42
" Fourier transform infrared spectroscopy and thermal analysis confirmed drug entrapment, while cytotoxicity studies performed in vitro on human keratinocytes, Saccharomyces cerevisiae models and Artemia salina, showed a dose-response relationship for nanoparticles and free drug."( Polymeric nanoparticles modified with fatty acids encapsulating betamethasone for anti-inflammatory treatment.
Ascensão, L; Fernandes, AS; Figueiredo, IV; Molpeceres, J; Reis, CP; Rijo, P; Roberto, A; Silva, CO, 2015
)
0.42
"36 g/day of β-glucan) and HOCO-DHA (50 g/day; dosage of DHA would be 3 g/day); and (4) all-purpose flour and control oil (50 g/day)."( Effect of consuming novel foods consisting high oleic canola oil, barley β-glucan, and DHA on cardiovascular disease risk in humans: the CONFIDENCE (Canola Oil and Fibre with DHA Enhanced) study - protocol for a randomized controlled trial.
Abraham, A; Ames, N; Jones, PJ; Ramprasath, VR; Thandapilly, SJ; Yang, S, 2015
)
0.42
"O/W emulsions were emulsified with equal dosage of egg yolk lecithin and increasing dosage of co-emulsifier (oleic acid or HS15)."( The research about microscopic structure of emulsion membrane in O/W emulsion by NMR and its influence to emulsion stability.
Chen, D; Chen, G; Chen, J; Fan, K; Lu, L; Xie, Y; Yang, F; Yang, L; Zeng, M; Zhang, S; Zhuang, Z, 2016
)
0.43
"With increasing dosage of co-emulsifier, emulsions showed two stable states, under which the signal intensity of characteristic group (orient to lipophilic core) of egg yolk lecithin disappeared in NMR of emulsions, but that (orient to aqueous phase) of co-emulsifiers only had some reduction at the second stable state."( The research about microscopic structure of emulsion membrane in O/W emulsion by NMR and its influence to emulsion stability.
Chen, D; Chen, G; Chen, J; Fan, K; Lu, L; Xie, Y; Yang, F; Yang, L; Zeng, M; Zhang, S; Zhuang, Z, 2016
)
0.43
" For sublingual application, sildenafil and its citrate were formulated in 2 different dosage forms: the first was a sublingual spray consisting of sildenafil in 2 microemulsion systems, oleic acid or propylene glycol (PG), and the second was sublingual tablets prepared with various granulated sublingual sprays adsorbed onto a silicate adsorbant (Florite(®) R), binders (Cyclocel(®) or EMDEX(®)), and disintegrants (Ac-Di-Sol(®) or Kollidon(®) CL)."( Rapid-Onset Sildenafil Sublingual Drug Delivery Systems: In Vitro Evaluation and In Vivo Pharmacokinetic Studies in Rabbits.
Chen, RN; Chou, PY; Ho, HO; Hsieh, CM; Sheu, MT, 2016
)
0.43
"SNEDDS could be a potential candidate for an oral dosage form of cyclovirobuxine D with improved bioavailability."( Design and optimization of self-nanoemulsifying drug delivery systems for improved bioavailability of cyclovirobuxine D.
Hou, X; Jia, XB; Ke, Z, 2016
)
0.43
"In many plant species, gene dosage is an important cause of phenotype variation."( Selective gene dosage by CRISPR-Cas9 genome editing in hexaploid Camelina sativa.
Bellec, Y; Faure, JD; Gissot, L; Kelemen, Z; Morineau, C; Nogué, F; Tellier, F, 2017
)
0.46
" Formulations were assessed based on their hypoglycaemic capacities in diabetic rats as compared to conventional subcutaneous dosage forms."( Low Molecular Weight Chitosan-Insulin Complexes Solubilized in a Mixture of Self-Assembled Labrosol and Plurol Oleaque and Their Glucose Reduction Activity in Rats.
Abu Farsakh, H; Al Remawi, MM; Badwan, AA; Elsayed, AM; Khaled, AH; Qinna, NA, 2018
)
0.48
" A series of dose-response experiments were conducted with albumin-bound fatty acid substrates (18:1n-9 and 20:1n-9) provided in concentrations up to 100µM."( The role of fatty acid desaturase (FADS) genes in oleic acid metabolism: FADS1 Δ7 desaturates 11-20:1 to 7,11-20:2.
Brenna, JT; Engel, MG; Kothapalli, KS; Lawrence, P; Park, HG; Vogt-Lowell, K, 2018
)
0.48
"Poor water solubility of clotrimazole (CLO) hinders development of the effective pharmaceutical dosage forms."( NANOEMULSION WITH CLOTRIMAZOLE - DESIGN AND OPTIMALIZATION OF MEAN DROPLET SIZE USING MICROFLUIDIZATION TECHNIQUE.
Sosnowska, K; Szymanska, E; Winnicka, K, 2017
)
0.46
" The combination dosage form increased the blood glucose lowering extent of insulin and blood insulin level compared with nanoparticles or beads alone."( Alginate-C18 Conjugate Nanoparticles Loaded in Tripolyphosphate-Cross-Linked Chitosan-Oleic Acid Conjugate-Coated Calcium Alginate Beads as Oral Insulin Carrier.
Alfatama, M; Lim, LY; Wong, TW, 2018
)
0.48
" Accordingly, ML-SNEP coated with Kollicoat Smartseal 30D and/or silicon dioxide could be an excellent dosage form that combine dual enhancement of CN solubilization and stabilization."( Stabilization benefits of single and multi-layer self-nanoemulsifying pellets: A poorly-water soluble model drug with hydrolytic susceptibility.
Abdel-Rahman, SI; Alanazi, FK; Shahba, AA, 2018
)
0.48
" We demonstrated by quantitative PCR that ATP synthase is downregulated in mesothelioma cells in response to regular dosing with BAMLET."( BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state.
Cheng, YY; Church, WB; Duff, AP; Håkansson, AP; Howell, VM; Hudson, AL; Knott, RB; Liu, GJ; Pinese, M; Rath, EM; Reid, G; Sarun, KH; Wang, YD; Weir, C, 2018
)
0.48
"The aim of the study was to investigate the endogenous metabolites of patients with psoriasis vulgaris which will be helpful for the diagnosis of the disease and to provide the evidence of pathogenesis and the formulation for the individualized dosage regimen."( Identification of psoriasis vulgaris biomarkers in human plasma by non-targeted metabolomics based on UPLC-Q-TOF/MS.
Li, H; Li, SS; Liu, Y; Wang, LP; Wu, XS; Xue, LF; Yin, GS, 2019
)
0.51
" It indicates that partially hydrolyzed polyacrylamide (HPAM), NaOL dosage and pH have a multiple effect on the removal efficiency of NaOL."( Removal of sodium oleate from synthetic manganese leaching solution by coagulation-dissolved air flotation.
Wang, S; Xue, J; Zhong, H, 2019
)
0.51
"The aim of this study was to develop a new dosage form as an alternative to the classical tablet forms of atorvastatin calcium (AtrCa)."( Formulation and In Vitro Evaluation of Self Microemulsifying Drug Delivery System Containing Atorvastatin Calcium.
Diril, M; Karasulu, HY; Türkyılmaz, GY, 2019
)
0.51
" The Langmuir technique was expanded using a dosing pump to exchange the subphase and deliver additional substances to the system."( Lipid-Protein Interactions in Langmuir Monolayers under Dynamically Varied Conditions.
Dopierała, K; Krajewska, M; Prochaska, K, 2020
)
0.56
" These results show the dominating impact of coupling charge interactions between the drug and the fatty acid carrier molecules to precisely adjust delivery rate and dosage from a contact lens."( Extended delivery of cationic drugs from contact lenses loaded with unsaturated fatty acids.
Briber, RM; Domszy, R; Fan, X; Hu, N; Torres-Luna, C; Yang, A; Yang, J, 2020
)
0.56
"To investigate the topical anti-inflammatory effect of oleic acid (OA), a monounsaturated fatty acid, into Pemulen® TR2-based semisolid dosage forms, employing a croton oil-induced irritant contact dermatitis model in mice."( Oleic acid exhibits an expressive anti-inflammatory effect in croton oil-induced irritant contact dermatitis without the occurrence of toxicological effects in mice.
Camponogara, C; Cruz, L; Oliveira, SM; Pegoraro, NS, 2021
)
0.62
"Oleic acid is a pharmaceutical excipient and has been widely used in many dosage forms."( Identification and direct determination of fatty acids profile in oleic acid by HPLC-CAD and MS-IT-TOF.
Chen, J; Chen, L; He, Y; Wang, B; Wu, C; Yuan, Y; Zhang, J; Zhao, X, 2021
)
0.62
"60%) at the maximum dosage of 100 ppm."( Larvicidal and repellent activity of N-methyl-1-adamantylamine and oleic acid a major derivative of bael tree ethanol leaf extracts against dengue mosquito vector and their biosafety on natural predator.
Al Farraj, DA; Ali, AM; Chellappandian, M; Elshikh, MS; Hunter, WB; Kalaivani, K; Karthi, S; Senthil-Nathan, S; Vasantha-Srinivasan, P; Veerabahu, C, 2022
)
0.72
" The thymoquinone-loaded oleoethosome treatment demonstrated a significantly greater extent of anti-inflammatory activity than the treatment with thymoquinone-loaded oleosomes or the conventional dosage form of the drug."( Oleic acid-based vesicular nanocarriers for topical delivery of the natural drug thymoquinone: Improvement of anti-inflammatory activity.
Barone, A; Bruno, MC; Cosco, D; Cristiano, MC; Fresta, M; Gagliardi, A; Mancuso, A; Paolino, D; Tarsitano, M, 2022
)
0.72
" The dosage forms currently on the market for OZP are administered via oral or intramuscular routes."( Development and evaluation of a drug-in-adhesive transdermal delivery system for delivery of olanzapine.
Banga, AK; Vora, D, 2022
)
0.72
"The effects of different dosage of NaCl and sucrose on the structural and functional properties of debranched quinoa starch-oleic acid complexes (DQS-OA) under baking were investigated."( Effects of NaCl and sucrose on the structural and functional properties of debranched quinoa starch-oleic acid complexes under baking.
Hu, A; Li, J; Li, W; Liu, G; Wang, M; Wang, W; Zheng, J; Zhu, X, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
EC 3.1.1.1 (carboxylesterase) inhibitorAny EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that inhibits the action of carboxylesterase (EC 3.1.1.1 ).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
Daphnia galeata metaboliteA Daphnia metabolite produced by the species Daphnia galeata.
solventA liquid that can dissolve other substances (solutes) without any change in their chemical composition.
antioxidantA substance that opposes oxidation or inhibits reactions brought about by dioxygen or peroxides.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
octadec-9-enoic acidAn octadecenoic acid with a double bond at C-9.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (406)

PathwayProteinsCompounds
Triacylglycerol Degradation TG(16:0/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(16:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(16:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(16:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(16:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(16:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(16:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(18:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/16:0)511
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/16:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/16:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/16:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/20:1(13Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/22:0)511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:1(11Z))511
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:0)513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:2(9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(6Z,9Z,12Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/18:3(9Z,12Z,15Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/20:1(11Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/16:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:1(9Z))58
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:1(11Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:2(9Z,12Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(6Z,9Z,12Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/18:3(9Z,12Z,15Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:1(11Z))59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/20:1(13Z))58
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/22:0)59
Triacylglycerol Degradation TG(18:1(9Z)/20:1(13Z)/22:1(13Z))59
Triacylglycerol Degradation TG(18:1(9Z)/22:0/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:0/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:0/22:0)511
Triacylglycerol Degradation TG(18:1(9Z)/22:0/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/16:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/22:0)512
Triacylglycerol Degradation TG(18:1(9Z)/22:1(13Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:1(11Z)/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:1(11Z)/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:1(11Z)/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(18:1(11Z)/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:2(9Z,12Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(6Z,9Z,12Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:2(9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(6Z,9Z,12Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:0/18:1(9Z)/22:0)513
Triacylglycerol Degradation TG(20:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(20:0/22:0/18:1(9Z))513
Triacylglycerol Degradation TG(20:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(20:1(11Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(20:1(11Z)/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(20:1(11Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/20:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(11Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(20:1(11Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(11Z)/22:1(13Z)/18:1(9Z))512
Triacylglycerol Degradation TG(20:1(13Z)/16:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/16:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:1(9Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:2(9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:1(11Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/20:1(13Z))510
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/22:0)511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(9Z)/22:1(13Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:2(9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(11Z)/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/20:1(13Z)/18:1(9Z))58
Triacylglycerol Degradation TG(20:1(13Z)/22:0/18:1(9Z))511
Triacylglycerol Degradation TG(20:1(13Z)/22:1(13Z)/18:1(9Z))511
Triacylglycerol Degradation TG(22:0/16:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:1(11Z))513
Triacylglycerol Degradation TG(22:0/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(22:0/18:1(9Z)/22:1(13Z))513
Triacylglycerol Degradation TG(22:0/18:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:2(9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(6Z,9Z,12Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/18:3(9Z,12Z,15Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/20:0/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/20:1(11Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:0/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(22:0/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:0/22:1(13Z)/18:1(9Z))513
Triacylglycerol Degradation TG(22:1(13Z)/16:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/16:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:1(9Z))511
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:2(9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(6Z,9Z,12Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/18:3(9Z,12Z,15Z))513
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:1(11Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/22:0)512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/22:1(13Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:2(9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(6Z,9Z,12Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/18:3(9Z,12Z,15Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(11Z)/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/20:1(13Z)/18:1(9Z))59
Triacylglycerol Degradation TG(22:1(13Z)/22:0/18:1(9Z))512
Triacylglycerol Degradation TG(22:1(13Z)/22:1(13Z)/18:1(9Z))511
Triacylglycerol Degradation TG(22:1(13Z)/18:1(9Z)/20:1(13Z))512
Triacylglycerol Degradation TG(18:3(9Z,12Z,15Z)/18:1(9Z)/18:3(9Z,12Z,15Z))512
Omega-9 fatty acid synthesis226
Linoleic acid metabolism affected by SARS-CoV-2513
Roles of ceramides in development of insulin resistance194
Mitochondrial beta-oxidation064
Elongation of (very) long chain fatty acids345
Octadecanoid formation from linoleic acid028
Mitochondrial LC-Fatty Acid Beta-Oxidation08
Omega-9 and other unsaturated fatty acids biosynthesis pathway017
Suberin biosynthesis022

Protein Targets (62)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency3.16230.003245.467312,589.2998AID2517
Chain A, HADH2 proteinHomo sapiens (human)Potency17.90080.025120.237639.8107AID886; AID893
Chain B, HADH2 proteinHomo sapiens (human)Potency17.90080.025120.237639.8107AID886; AID893
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency89.12510.631035.7641100.0000AID504339
LuciferasePhotinus pyralis (common eastern firefly)Potency66.22560.007215.758889.3584AID1224835; AID588342
thioredoxin reductaseRattus norvegicus (Norway rat)Potency89.12510.100020.879379.4328AID588453
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency55.10583.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency30.63790.006038.004119,952.5996AID1159521
ATAD5 protein, partialHomo sapiens (human)Potency14.57500.004110.890331.5287AID504467
USP1 protein, partialHomo sapiens (human)Potency37.64600.031637.5844354.8130AID504865; AID743255
Microtubule-associated protein tauHomo sapiens (human)Potency28.18380.180013.557439.8107AID1460
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency61.50380.000657.913322,387.1992AID1259378
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency1.72290.003041.611522,387.1992AID1159552
farnesoid X nuclear receptorHomo sapiens (human)Potency31.62280.375827.485161.6524AID588526
estrogen nuclear receptor alphaHomo sapiens (human)Potency27.69950.000229.305416,493.5996AID743069; AID743075; AID743078
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency32.20130.001019.414170.9645AID588537; AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency9.77120.023723.228263.5986AID743223
serine-protein kinase ATM isoform aHomo sapiens (human)Potency15.84890.707925.111941.2351AID485349
Bloom syndrome protein isoform 1Homo sapiens (human)Potency35.48130.540617.639296.1227AID2528
chromobox protein homolog 1Homo sapiens (human)Potency79.43280.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency5.62343.548119.542744.6684AID743266
heat shock protein beta-1Homo sapiens (human)Potency49.29710.042027.378961.6448AID743210; AID743228
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency10.62130.168316.404067.0158AID720504
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency15.84890.010323.856763.0957AID2662
gemininHomo sapiens (human)Potency16.50890.004611.374133.4983AID624296; AID624297
DNA polymerase kappa isoform 1Homo sapiens (human)Potency23.77810.031622.3146100.0000AID588579
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency32.19680.005612.367736.1254AID624032
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency31.62280.251215.843239.8107AID504327
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency5.01196.309660.2008112.2020AID720707
Cellular tumor antigen p53Homo sapiens (human)Potency68.58960.002319.595674.0614AID651631
Nuclear receptor ROR-gammaHomo sapiens (human)Potency37.57800.026622.448266.8242AID651802
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)Potency35.48130.015823.527344.6684AID651778
Rap guanine nucleotide exchange factor 4Homo sapiens (human)Potency19.95263.981146.7448112.2020AID720708
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Fatty-acid amide hydrolase 1Homo sapiens (human)Ki6.00000.00061.27476.0000AID346660
Prostaglandin G/H synthase 1 Bos taurus (cattle)IC50 (µMol)500.00000.00051.41288.2000AID360928
Sterol O-acyltransferase 1Rattus norvegicus (Norway rat)IC50 (µMol)1,000.00000.00580.66266.0000AID241990
TrypsinSus scrofa (pig)IC50 (µMol)200.00000.50000.50000.5000AID402793
Fatty acid-binding protein, liverRattus norvegicus (Norway rat)Ki1.54000.01501.24876.9200AID407366; AID407369
Coagulation factor VIIHomo sapiens (human)IC50 (µMol)80.00000.00020.83363.3000AID402795
DNA topoisomerase 1Homo sapiens (human)IC50 (µMol)31.00000.02101.862610.0000AID361445
AromataseHomo sapiens (human)IC50 (µMol)32.70000.00001.290410.0000AID376617
Tissue factorHomo sapiens (human)IC50 (µMol)80.00000.00010.734410.0000AID402795
Fatty acid-binding protein, adipocyteHomo sapiens (human)IC50 (µMol)26.10000.22101.22532.7500AID483947
Fatty acid-binding protein, adipocyteHomo sapiens (human)Ki0.84250.00200.92916.8000AID1312065; AID307907
Tyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)IC50 (µMol)6.20000.00053.49849.7600AID1657531
Sterol O-acyltransferase 1Homo sapiens (human)IC50 (µMol)1,000.00000.02501.79758.0000AID241602; AID241603
Prostaglandin G/H synthase 2Ovis aries (sheep)IC50 (µMol)500.00000.00101.453910.0000AID360927
Fatty acid-binding protein 5Homo sapiens (human)Ki0.24800.24802.77129.3700AID307909
Transient receptor potential cation channel subfamily V member 2Rattus norvegicus (Norway rat)IC50 (µMol)10.00000.03701.93458.6000AID1400243; AID1400244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Adipocyte Lipid-binding ProteinMus musculus (house mouse)Kd0.30000.30000.30000.3000AID977611
Chain A, SERUM ALBUMINHomo sapiens (human)Kd0.00850.00850.04970.0910AID977611
Chain A, SERUM ALBUMINHomo sapiens (human)Kd0.00850.00850.04970.0910AID977611
Chain A, MUSCLE FATTY ACID BINDING PROTEINHomo sapiens (human)Kd0.43000.28000.78331.6400AID977611
Chain A, MUSCLE FATTY ACID BINDING PROTEINHomo sapiens (human)Kd0.43000.28000.78331.6400AID977611
Chain A, MUSCLE FATTY ACID BINDING PROTEINHomo sapiens (human)Kd0.43000.28000.78331.6400AID977611
Chain A, BCL-2-RELATED PROTEIN A1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
putative potassium channel subunitHomo sapiens (human)EC50 (µMol)10.41000.24005.530011.0800AID2121
bcl-2-like protein 11 isoform 1Homo sapiens (human)EC50 (µMol)350.00008.0570121.1218338.0000AID2765
Fatty acid-binding protein, liverHomo sapiens (human)Kd0.55000.20000.55000.9000AID407370; AID407371
Peroxisome proliferator-activated receptor alphaHomo sapiens (human)EC50 (µMol)36.00000.00061.607410.0000AID1901640
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (386)

Processvia Protein(s)Taxonomy
fatty acid catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
arachidonic acid metabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
positive regulation of vasoconstrictionFatty-acid amide hydrolase 1Homo sapiens (human)
monoacylglycerol catabolic processFatty-acid amide hydrolase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1 Bos taurus (cattle)
cellular oxidant detoxificationProstaglandin G/H synthase 1 Bos taurus (cattle)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
positive regulation of fatty acid beta-oxidationFatty acid-binding protein, liverHomo sapiens (human)
response to vitamin B3Fatty acid-binding protein, liverHomo sapiens (human)
negative regulation of apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic processFatty acid-binding protein, liverHomo sapiens (human)
intestinal absorptionFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hydrogen peroxideFatty acid-binding protein, liverHomo sapiens (human)
cellular response to hypoxiaFatty acid-binding protein, liverHomo sapiens (human)
cellular oxidant detoxificationFatty acid-binding protein, liverHomo sapiens (human)
fatty acid transportFatty acid-binding protein, liverHomo sapiens (human)
response to hypoxiaCoagulation factor VIIHomo sapiens (human)
positive regulation of leukocyte chemotaxisCoagulation factor VIIHomo sapiens (human)
blood coagulationCoagulation factor VIIHomo sapiens (human)
circadian rhythmCoagulation factor VIIHomo sapiens (human)
response to carbon dioxideCoagulation factor VIIHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayCoagulation factor VIIHomo sapiens (human)
protein processingCoagulation factor VIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor VIIHomo sapiens (human)
positive regulation of cell migrationCoagulation factor VIIHomo sapiens (human)
animal organ regenerationCoagulation factor VIIHomo sapiens (human)
positive regulation of TOR signalingCoagulation factor VIIHomo sapiens (human)
response to estradiolCoagulation factor VIIHomo sapiens (human)
response to vitamin KCoagulation factor VIIHomo sapiens (human)
response to genisteinCoagulation factor VIIHomo sapiens (human)
response to estrogenCoagulation factor VIIHomo sapiens (human)
positive regulation of positive chemotaxisCoagulation factor VIIHomo sapiens (human)
response to growth hormoneCoagulation factor VIIHomo sapiens (human)
response to cholesterolCoagulation factor VIIHomo sapiens (human)
response to thyroxineCoagulation factor VIIHomo sapiens (human)
response to Thyroid stimulating hormoneCoagulation factor VIIHomo sapiens (human)
response to 2,3,7,8-tetrachlorodibenzodioxineCoagulation factor VIIHomo sapiens (human)
response to astaxanthinCoagulation factor VIIHomo sapiens (human)
response to thyrotropin-releasing hormoneCoagulation factor VIIHomo sapiens (human)
DNA topological changeDNA topoisomerase 1Homo sapiens (human)
chromatin remodelingDNA topoisomerase 1Homo sapiens (human)
circadian rhythmDNA topoisomerase 1Homo sapiens (human)
response to xenobiotic stimulusDNA topoisomerase 1Homo sapiens (human)
programmed cell deathDNA topoisomerase 1Homo sapiens (human)
phosphorylationDNA topoisomerase 1Homo sapiens (human)
peptidyl-serine phosphorylationDNA topoisomerase 1Homo sapiens (human)
circadian regulation of gene expressionDNA topoisomerase 1Homo sapiens (human)
embryonic cleavageDNA topoisomerase 1Homo sapiens (human)
chromosome segregationDNA topoisomerase 1Homo sapiens (human)
DNA replicationDNA topoisomerase 1Homo sapiens (human)
negative regulation of chronic inflammatory responseAromataseHomo sapiens (human)
steroid biosynthetic processAromataseHomo sapiens (human)
estrogen biosynthetic processAromataseHomo sapiens (human)
androgen catabolic processAromataseHomo sapiens (human)
syncytium formationAromataseHomo sapiens (human)
negative regulation of macrophage chemotaxisAromataseHomo sapiens (human)
sterol metabolic processAromataseHomo sapiens (human)
female genitalia developmentAromataseHomo sapiens (human)
mammary gland developmentAromataseHomo sapiens (human)
uterus developmentAromataseHomo sapiens (human)
prostate gland growthAromataseHomo sapiens (human)
testosterone biosynthetic processAromataseHomo sapiens (human)
positive regulation of estradiol secretionAromataseHomo sapiens (human)
female gonad developmentAromataseHomo sapiens (human)
response to estradiolAromataseHomo sapiens (human)
positive regulation of gene expressionTissue factorHomo sapiens (human)
positive regulation of interleukin-8 productionTissue factorHomo sapiens (human)
positive regulation of endothelial cell proliferationTissue factorHomo sapiens (human)
activation of plasma proteins involved in acute inflammatory responseTissue factorHomo sapiens (human)
activation of blood coagulation via clotting cascadeTissue factorHomo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic processTissue factorHomo sapiens (human)
blood coagulationTissue factorHomo sapiens (human)
positive regulation of platelet-derived growth factor receptor signaling pathwayTissue factorHomo sapiens (human)
protein processingTissue factorHomo sapiens (human)
positive regulation of cell migrationTissue factorHomo sapiens (human)
positive regulation of TOR signalingTissue factorHomo sapiens (human)
positive regulation of angiogenesisTissue factorHomo sapiens (human)
positive regulation of positive chemotaxisTissue factorHomo sapiens (human)
cytokine-mediated signaling pathwayTissue factorHomo sapiens (human)
response to bacteriumFatty acid-binding protein, adipocyteHomo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein, adipocyteHomo sapiens (human)
cholesterol homeostasisFatty acid-binding protein, adipocyteHomo sapiens (human)
negative regulation of DNA-templated transcriptionFatty acid-binding protein, adipocyteHomo sapiens (human)
positive regulation of inflammatory responseFatty acid-binding protein, adipocyteHomo sapiens (human)
white fat cell differentiationFatty acid-binding protein, adipocyteHomo sapiens (human)
brown fat cell differentiationFatty acid-binding protein, adipocyteHomo sapiens (human)
cellular response to lithium ionFatty acid-binding protein, adipocyteHomo sapiens (human)
cellular response to tumor necrosis factorFatty acid-binding protein, adipocyteHomo sapiens (human)
positive regulation of cold-induced thermogenesisFatty acid-binding protein, adipocyteHomo sapiens (human)
fatty acid transportFatty acid-binding protein, adipocyteHomo sapiens (human)
angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell proliferationProtein kinase C alpha typeHomo sapiens (human)
desmosome assemblyProtein kinase C alpha typeHomo sapiens (human)
chromatin remodelingProtein kinase C alpha typeHomo sapiens (human)
protein phosphorylationProtein kinase C alpha typeHomo sapiens (human)
mitotic nuclear membrane disassemblyProtein kinase C alpha typeHomo sapiens (human)
cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cardiac muscle hypertrophyProtein kinase C alpha typeHomo sapiens (human)
peptidyl-serine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
peptidyl-threonine phosphorylationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell migrationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of lipopolysaccharide-mediated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
negative regulation of glial cell apoptotic processProtein kinase C alpha typeHomo sapiens (human)
regulation of mRNA stabilityProtein kinase C alpha typeHomo sapiens (human)
positive regulation of blood vessel endothelial cell migrationProtein kinase C alpha typeHomo sapiens (human)
post-translational protein modificationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of macrophage differentiationProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiogenesisProtein kinase C alpha typeHomo sapiens (human)
positive regulation of bone resorptionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of cell adhesionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of mitotic cell cycleProtein kinase C alpha typeHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeProtein kinase C alpha typeHomo sapiens (human)
response to interleukin-1Protein kinase C alpha typeHomo sapiens (human)
regulation of platelet aggregationProtein kinase C alpha typeHomo sapiens (human)
apoptotic signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of angiotensin-activated signaling pathwayProtein kinase C alpha typeHomo sapiens (human)
positive regulation of dense core granule biogenesisProtein kinase C alpha typeHomo sapiens (human)
intracellular signal transductionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of insulin secretionProtein kinase C alpha typeHomo sapiens (human)
positive regulation of JUN kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of signal transductionTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
actin cytoskeleton organizationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of endocytosisTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of vascular endothelial growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulum unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of intracellular protein transportTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cellular response to unfolded proteinTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylationTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
platelet-derived growth factor receptor-beta signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor recyclingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of MAP kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of insulin receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of type I interferon-mediated signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
growth hormone receptor signaling pathway via JAK-STATTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of protein tyrosine kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of ERK1 and ERK2 cascadeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
regulation of hepatocyte growth factor receptor signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of IRE1-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
negative regulation of PERK-mediated unfolded protein responseTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
positive regulation of receptor catabolic processTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
cholesterol metabolic processSterol O-acyltransferase 1Homo sapiens (human)
macrophage derived foam cell differentiationSterol O-acyltransferase 1Homo sapiens (human)
cholesterol storageSterol O-acyltransferase 1Homo sapiens (human)
cholesterol effluxSterol O-acyltransferase 1Homo sapiens (human)
very-low-density lipoprotein particle assemblySterol O-acyltransferase 1Homo sapiens (human)
low-density lipoprotein particle clearanceSterol O-acyltransferase 1Homo sapiens (human)
cholesterol homeostasisSterol O-acyltransferase 1Homo sapiens (human)
positive regulation of amyloid precursor protein biosynthetic processSterol O-acyltransferase 1Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to hypoxiaNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron migrationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
response to amphetamineNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-templated transcriptionNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
adult locomotory behaviorNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
post-embryonic developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system projection neuron axonogenesisNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
habenula developmentNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to oxidative stressNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of dopamine metabolic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopamine biosynthetic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron maturationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of respiratory gaseous exchangeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
fat cell differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
positive regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
neuron apoptotic processNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
general adaptation syndromeNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
canonical Wnt signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cellular response to corticotropin-releasing hormone stimulusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
midbrain dopaminergic neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of apoptotic signaling pathwayNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor subfamily 4 group A member 2Homo sapiens (human)
central nervous system neuron differentiationNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
glucose metabolic processFatty acid-binding protein 5Homo sapiens (human)
lipid metabolic processFatty acid-binding protein 5Homo sapiens (human)
phosphatidylcholine biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
epidermis developmentFatty acid-binding protein 5Homo sapiens (human)
negative regulation of glucose transmembrane transportFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
regulation of prostaglandin biosynthetic processFatty acid-binding protein 5Homo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayFatty acid-binding protein 5Homo sapiens (human)
glucose homeostasisFatty acid-binding protein 5Homo sapiens (human)
regulation of sensory perception of painFatty acid-binding protein 5Homo sapiens (human)
regulation of retrograde trans-synaptic signaling by endocanabinoidFatty acid-binding protein 5Homo sapiens (human)
positive regulation of cold-induced thermogenesisFatty acid-binding protein 5Homo sapiens (human)
lipid transport across blood-brain barrierFatty acid-binding protein 5Homo sapiens (human)
fatty acid transportFatty acid-binding protein 5Homo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
generation of precursor metabolites and energyPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid beta-oxidationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
embryo implantationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cholesterol metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell population proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
axon ensheathmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid catabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of gene expressionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
regulation of skeletal muscle satellite cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell-substrate adhesionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to nutrient levelsPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of skeletal muscle tissue regenerationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of myoblast differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
decidualizationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of epithelial cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
keratinocyte migrationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
adipose tissue developmentPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fat cell proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cellular response to hypoxiaPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
energy homeostasisPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
apoptotic signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
glucose transmembrane transportPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of myoblast proliferationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor deltaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
negative regulation of cytokine production involved in inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of reactive oxygen species biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of hepatocyte apoptotic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of signaling receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of ATP biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transformation of host cell by virusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to hypoxiaPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
heart developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to nutrientPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
epidermis developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to starvationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of cellular ketone metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of macrophage derived foam cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cholesterol storagePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of sequestering of triglyceridePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
intracellular receptor signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid beta-oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of appetitePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to insulinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
circadian regulation of gene expressionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
behavioral response to nicotinePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
wound healingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipoprotein metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of circadian rhythmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
steroid hormone mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
response to ethanolPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of gluconeogenesisPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of blood pressurePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of glycolytic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of DNA-templated transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nitric oxide metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid oxidationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of lipid biosynthetic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of inflammatory responsePeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of cell growth involved in cardiac muscle cell developmentPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
enamel mineralizationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cellular response to fructose stimulusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of miRNA transcriptionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
negative regulation of leukocyte cell-cell adhesionPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
regulation of fatty acid transportPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
hormone-mediated signaling pathwayPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
positive regulation of fatty acid metabolic processPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cell differentiationPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 4Homo sapiens (human)
G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 4Homo sapiens (human)
calcium-ion regulated exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of exocytosisRap guanine nucleotide exchange factor 4Homo sapiens (human)
insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
positive regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of synaptic vesicle cycleRap guanine nucleotide exchange factor 4Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 4Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (110)

Processvia Protein(s)Taxonomy
protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
phospholipid bindingFatty-acid amide hydrolase 1Homo sapiens (human)
fatty acid amide hydrolase activityFatty-acid amide hydrolase 1Homo sapiens (human)
identical protein bindingFatty-acid amide hydrolase 1Homo sapiens (human)
acylglycerol lipase activityFatty-acid amide hydrolase 1Homo sapiens (human)
amidase activityFatty-acid amide hydrolase 1Homo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1 Bos taurus (cattle)
heme bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
metal ion bindingProstaglandin G/H synthase 1 Bos taurus (cattle)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingFatty acid-binding protein, liverHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, liverHomo sapiens (human)
protein bindingFatty acid-binding protein, liverHomo sapiens (human)
phospholipid bindingFatty acid-binding protein, liverHomo sapiens (human)
antioxidant activityFatty acid-binding protein, liverHomo sapiens (human)
bile acid bindingFatty acid-binding protein, liverHomo sapiens (human)
oleic acid bindingFatty acid-binding protein, liverHomo sapiens (human)
heterocyclic compound bindingFatty acid-binding protein, liverHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, liverHomo sapiens (human)
serine-type endopeptidase activityCoagulation factor VIIHomo sapiens (human)
signaling receptor bindingCoagulation factor VIIHomo sapiens (human)
calcium ion bindingCoagulation factor VIIHomo sapiens (human)
protein bindingCoagulation factor VIIHomo sapiens (human)
serine-type peptidase activityCoagulation factor VIIHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA bindingDNA topoisomerase 1Homo sapiens (human)
chromatin bindingDNA topoisomerase 1Homo sapiens (human)
double-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
single-stranded DNA bindingDNA topoisomerase 1Homo sapiens (human)
RNA bindingDNA topoisomerase 1Homo sapiens (human)
DNA topoisomerase type I (single strand cut, ATP-independent) activityDNA topoisomerase 1Homo sapiens (human)
protein serine/threonine kinase activityDNA topoisomerase 1Homo sapiens (human)
protein bindingDNA topoisomerase 1Homo sapiens (human)
ATP bindingDNA topoisomerase 1Homo sapiens (human)
DNA binding, bendingDNA topoisomerase 1Homo sapiens (human)
protein domain specific bindingDNA topoisomerase 1Homo sapiens (human)
supercoiled DNA bindingDNA topoisomerase 1Homo sapiens (human)
iron ion bindingAromataseHomo sapiens (human)
steroid hydroxylase activityAromataseHomo sapiens (human)
electron transfer activityAromataseHomo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenAromataseHomo sapiens (human)
oxygen bindingAromataseHomo sapiens (human)
heme bindingAromataseHomo sapiens (human)
aromatase activityAromataseHomo sapiens (human)
serine-type endopeptidase activityTissue factorHomo sapiens (human)
protease bindingTissue factorHomo sapiens (human)
protein bindingTissue factorHomo sapiens (human)
phospholipid bindingTissue factorHomo sapiens (human)
cytokine receptor activityTissue factorHomo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein, adipocyteHomo sapiens (human)
long-chain fatty acid bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
hormone receptor bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
fatty acid bindingFatty acid-binding protein, adipocyteHomo sapiens (human)
protein kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
calcium,diacylglycerol-dependent serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
integrin bindingProtein kinase C alpha typeHomo sapiens (human)
protein bindingProtein kinase C alpha typeHomo sapiens (human)
ATP bindingProtein kinase C alpha typeHomo sapiens (human)
zinc ion bindingProtein kinase C alpha typeHomo sapiens (human)
enzyme bindingProtein kinase C alpha typeHomo sapiens (human)
histone H3T6 kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine kinase activityProtein kinase C alpha typeHomo sapiens (human)
protein serine/threonine kinase activityProtein kinase C alpha typeHomo sapiens (human)
diacylglycerol bindingProtein kinase C alpha typeHomo sapiens (human)
RNA bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
insulin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
zinc ion bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
enzyme bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
receptor tyrosine kinase bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cadherin bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
ephrin receptor bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein phosphatase 2A bindingTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
non-membrane spanning protein tyrosine phosphatase activityTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
fatty-acyl-CoA bindingSterol O-acyltransferase 1Homo sapiens (human)
sterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
protein bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol bindingSterol O-acyltransferase 1Homo sapiens (human)
cholesterol O-acyltransferase activitySterol O-acyltransferase 1Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear receptor activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
beta-catenin bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
zinc ion bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear retinoid X receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein heterodimerization activityNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear glucocorticoid receptor bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
retinoic acid bindingFatty acid-binding protein 5Homo sapiens (human)
long-chain fatty acid transmembrane transporter activityFatty acid-binding protein 5Homo sapiens (human)
fatty acid bindingFatty acid-binding protein 5Homo sapiens (human)
protein bindingFatty acid-binding protein 5Homo sapiens (human)
lipid bindingFatty acid-binding protein 5Homo sapiens (human)
identical protein bindingFatty acid-binding protein 5Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
linoleic acid bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
sequence-specific double-stranded DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
transcription coactivator bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear steroid receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nuclear receptor activityPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
zinc ion bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
lipid bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
phosphatase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein domain specific bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
mitogen-activated protein kinase kinase kinase bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
ubiquitin conjugating enzyme bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
sequence-specific DNA bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
protein-containing complex bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
NFAT protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
MDM2/MDM4 family protein bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
DNA-binding transcription factor bindingPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
protein-macromolecule adaptor activityRap guanine nucleotide exchange factor 4Homo sapiens (human)
small GTPase bindingRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (63)

Processvia Protein(s)Taxonomy
endoplasmic reticulum membraneFatty-acid amide hydrolase 1Homo sapiens (human)
cytoskeletonFatty-acid amide hydrolase 1Homo sapiens (human)
organelle membraneFatty-acid amide hydrolase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1 Bos taurus (cattle)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
nucleoplasmFatty acid-binding protein, liverHomo sapiens (human)
peroxisomal matrixFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
apical cortexFatty acid-binding protein, liverHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, liverHomo sapiens (human)
protein-containing complexFatty acid-binding protein, liverHomo sapiens (human)
nucleusFatty acid-binding protein, liverHomo sapiens (human)
cytosolFatty acid-binding protein, liverHomo sapiens (human)
extracellular regionCoagulation factor VIIHomo sapiens (human)
endoplasmic reticulum lumenCoagulation factor VIIHomo sapiens (human)
Golgi lumenCoagulation factor VIIHomo sapiens (human)
plasma membraneCoagulation factor VIIHomo sapiens (human)
vesicleCoagulation factor VIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor VIIHomo sapiens (human)
serine-type peptidase complexCoagulation factor VIIHomo sapiens (human)
extracellular spaceCoagulation factor VIIHomo sapiens (human)
nuclear chromosomeDNA topoisomerase 1Homo sapiens (human)
P-bodyDNA topoisomerase 1Homo sapiens (human)
fibrillar centerDNA topoisomerase 1Homo sapiens (human)
male germ cell nucleusDNA topoisomerase 1Homo sapiens (human)
nucleusDNA topoisomerase 1Homo sapiens (human)
nucleoplasmDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
perikaryonDNA topoisomerase 1Homo sapiens (human)
protein-DNA complexDNA topoisomerase 1Homo sapiens (human)
nucleolusDNA topoisomerase 1Homo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
endoplasmic reticulum membraneAromataseHomo sapiens (human)
membraneAromataseHomo sapiens (human)
endoplasmic reticulumAromataseHomo sapiens (human)
extracellular spaceTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
external side of plasma membraneTissue factorHomo sapiens (human)
cell surfaceTissue factorHomo sapiens (human)
membraneTissue factorHomo sapiens (human)
collagen-containing extracellular matrixTissue factorHomo sapiens (human)
serine-type peptidase complexTissue factorHomo sapiens (human)
plasma membraneTissue factorHomo sapiens (human)
nucleusFatty acid-binding protein, adipocyteHomo sapiens (human)
cytoplasmFatty acid-binding protein, adipocyteHomo sapiens (human)
lipid dropletFatty acid-binding protein, adipocyteHomo sapiens (human)
cytosolFatty acid-binding protein, adipocyteHomo sapiens (human)
extracellular exosomeFatty acid-binding protein, adipocyteHomo sapiens (human)
cytosolFatty acid-binding protein, adipocyteHomo sapiens (human)
nucleusFatty acid-binding protein, adipocyteHomo sapiens (human)
ciliary basal bodyProtein kinase C alpha typeHomo sapiens (human)
nucleoplasmProtein kinase C alpha typeHomo sapiens (human)
cytoplasmProtein kinase C alpha typeHomo sapiens (human)
mitochondrionProtein kinase C alpha typeHomo sapiens (human)
endoplasmic reticulumProtein kinase C alpha typeHomo sapiens (human)
cytosolProtein kinase C alpha typeHomo sapiens (human)
plasma membraneProtein kinase C alpha typeHomo sapiens (human)
mitochondrial membraneProtein kinase C alpha typeHomo sapiens (human)
perinuclear region of cytoplasmProtein kinase C alpha typeHomo sapiens (human)
extracellular exosomeProtein kinase C alpha typeHomo sapiens (human)
alphav-beta3 integrin-PKCalpha complexProtein kinase C alpha typeHomo sapiens (human)
plasma membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial matrixTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytosolTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
mitochondrial cristaTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endosome lumenTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
sorting endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmic side of endoplasmic reticulum membraneTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
protein-containing complexTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
cytoplasmTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
early endosomeTyrosine-protein phosphatase non-receptor type 1Homo sapiens (human)
endoplasmic reticulumSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
membraneSterol O-acyltransferase 1Homo sapiens (human)
endoplasmic reticulum membraneSterol O-acyltransferase 1Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
cytoplasmNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nuclear speckNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
chromatinNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
protein-containing complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
transcription regulator complexNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor subfamily 4 group A member 2Homo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
extracellular regionFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
nucleoplasmFatty acid-binding protein 5Homo sapiens (human)
cytoplasmFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
plasma membraneFatty acid-binding protein 5Homo sapiens (human)
postsynaptic densityFatty acid-binding protein 5Homo sapiens (human)
secretory granule membraneFatty acid-binding protein 5Homo sapiens (human)
azurophil granule lumenFatty acid-binding protein 5Homo sapiens (human)
synapseFatty acid-binding protein 5Homo sapiens (human)
extracellular exosomeFatty acid-binding protein 5Homo sapiens (human)
cytosolFatty acid-binding protein 5Homo sapiens (human)
nucleusFatty acid-binding protein 5Homo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor deltaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleoplasmPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
chromatinPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
nucleusPeroxisome proliferator-activated receptor alphaHomo sapiens (human)
cytosolRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
hippocampal mossy fiber to CA3 synapseRap guanine nucleotide exchange factor 4Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 4Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (213)

Assay IDTitleYearJournalArticle
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1083124Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 100 umol/L after 24 hr (Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1101915Nematicidal activity against Caenorhabditis elegans assessed as mortality at 100 ug/ml after 24 hr by microscopic analysis2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1617377Drug metabolism in human liver microsomes assessed as microsomal/soluble epoxide hydrolase mediated formation of [+O + H2O] metabolites at 1 uM after 60 mins in absence of NADPH by LC-MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID330320Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of fetal calf serum assessed viral RNA level at 0.1 mM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID627880Inhibition of recombinant His-tagged human DNA polymerase lambda using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1082343Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID407369Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP low binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID539491Lipophilicity, log K of the compound in methanol-water mixture by HPLC2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.
AID539492Potentiation of theophylline transdermal permeation in pig ear skin after 24 hrs by Franz diffusion cells method relative to untreated control2010Bioorganic & medicinal chemistry, Dec-15, Volume: 18, Issue:24
Investigating the activity of 2-substituted alkyl-6-(2,5-dioxopyrrolidin-1-yl)hexanoates as skin penetration enhancers.
AID1312081Displacement of 1,8-ANS from His6-tagged FABP4 (unknown origin) R106A mutant expressed in Escherichia coli BL21(DE3) cells at 25 uM by fluorescence assay relative to control2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
AID628060Inhibition of recombinant His-tagged human DNA polymerase lambda using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1082335Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID627876Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID247402Growth inhibitory activity against human cancer cell line in the NCI's anticancer drug screening program2005Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
CHMIS-C: a comprehensive herbal medicine information system for cancer.
AID1083127Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1082330Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under dark conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1657531Inhibition of PTP1B (unknown origin) using pNPP as substrate incubated for 30 mins by photometric method2020Journal of natural products, 05-22, Volume: 83, Issue:5
PTP1B-Inhibiting Branched-Chain Fatty Acid Dimers from
AID360927Inhibition of sheep COX2-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID1519392Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID402794Octanol-water partition coefficient, log P of the compound1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID627875Inhibition of histidine-tagged human DNA polymerase gamma using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID376615Inhibition of aromatase in human placental microsomes at 20 ug/ml by radiometric method relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID1082336Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID627980Cytotoxicity against mouse RAW264.7 cells at 5 uM2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1519391Antibacterial activity against Staphylococcus aureus NCTC 4163 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1083132Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID671697Lipophilicity, log K of the compound by RP-HPLC analysis2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Investigation of substituted 6-aminohexanoates as skin penetration enhancers.
AID1519396Antibacterial activity against Escherichia coli ATCC 25922 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1101905Antimicrobial activity against Aspergillus parasiticus at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1101917Antimicrobial activity against Candida parapsilosis at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1082357Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under light conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID241602Inhibitory activity against human Acyl coenzyme A:cholesterol acyltransferase 12004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas.
AID1519397Antibacterial activity against Escherichia coli NCTC 8196 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1082334Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under light conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID319012Activity at gramicidin A negative channel 15 assessed as increase in single channel current2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID346660Inhibition of FAAH2008Journal of medicinal chemistry, Dec-11, Volume: 51, Issue:23
Discovery and development of fatty acid amide hydrolase (FAAH) inhibitors.
AID627982Antiinflammatory activity in mouse assessed as inhibition of TPA-induced mouse ear edema at 500 ug/ear administered 30 mins before TPA challenge measured after 7 hrs relative to untreated control2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID164149Activation of purified human recombinant Protein Kinase C alpha2003Bioorganic & medicinal chemistry letters, May-05, Volume: 13, Issue:9
Efficient synthesis of 3-trifluoromethylphenyldiazirinyl oleic acid derivatives and their biological activity for protein kinase C.
AID1901642Agonist activity at human PPARdelta expressed in HEK293 cells by luciferase/beta-galactosidase reporter gene assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1617374Drug metabolism in human liver microsomes assessed as CYP450-mediated formation of [+O] metabolites at 1 uM after 60 mins in presence of NADPH by LC-MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID196759Inhibition of rat glial cell gap junction at the concentration of 50 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID614100Antimicrobial activity against Staphylococcus aureus ATCC 9144 after 24 hrs using thiazoyl blue by agar overlay bioautography method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Tylosema esculentum extractives and their bioactivity.
AID1083134Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1082342Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID658576Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of isoniazid-mediated antibacterial activity measuring ratio of isoniazid MIC to isoniazid and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1082337Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082344Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1083136Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1519395Antibacterial activity against Enterococcus hirae ATCC 10541 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID671699Potentiation of theophylline transdermal permeation in pig ear skin assessed as enhancement ratio at 20 mg after 24 hrs by Franz diffusion cell method2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Investigation of substituted 6-aminohexanoates as skin penetration enhancers.
AID1082328Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under dark conditions measured 72 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID241603Inhibitory activity against human Acyl coenzyme A:cholesterol acyltransferase 22004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1312066Binding affinity to His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as change in melting temperature at 50 uM after 30 mins by SYPRO orange dye based thermal stability shift assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
AID1083129Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1082355Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under light conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID455092Binding affinity to soybean LO12009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1.
AID1082331Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under light conditions measured 72 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID307907Displacement of 1,8-ANS from aFABP by fluorescence based-assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
AID1082359Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under light conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID483947Displacement of 8-anilino-1-naphthalene-sulfonic acid from human His-FABP4 expressed in Escherichia coli BL21 (DE3) cells after 3 mins2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.
AID1082358Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under light conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID402798Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID376618Inhibition of aromatase in human SKBR3 cells at 100 uM relative to control2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID307909Displacement of 1,8-ANS from eFABP by fluorescence based-assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
AID407370Binding affinity to L-FABP high binding affinity site by titration calorimetry method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1338209Inhibition of Staphylococcus aureus FabI using t-o-NAC-thioester as substrate by spectrophometric method2017European journal of medicinal chemistry, Jan-05, Volume: 125Antitubercular activity of 1,2,3-triazolyl fatty acid derivatives.
AID455082Competitive inhibition of soybean LO1 assessed as increase in arachidonic acid/linoleic acid ratio at 55 uM by substrate specificity assay2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1.
AID319015Partition coefficient (x10-4) across dioleoylphosphatidylcholine bilayer2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID614104Antimicrobial activity against Escherichia coli ATCC 11229 after 24 hrs using thiazoyl blue by agar overlay bioautography method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Tylosema esculentum extractives and their bioactivity.
AID376617Inhibition of aromatase in human placental microsomes by radiometric method2006Journal of natural products, Apr, Volume: 69, Issue:4
Interference by naturally occurring fatty acids in a noncellular enzyme-based aromatase bioassay.
AID40631Inhibitory activity on germination of Bacillus subtilis PCI219 spores was determined at 2 x 10E-4 M1982Journal of medicinal chemistry, Mar, Volume: 25, Issue:3
Quantitative structure-inhibitory activity relationships of phenols and fatty acids for Bacillus subtilis spore germination.
AID1101904Antimicrobial activity against Fusarium oxysporum at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1082351Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.5% under dark conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082349Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under dark conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1400244Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of CBD-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID1400243Antagonist activity at recombinant rat TRPV2 expressed in HEK293 cells assessed as inhibition of LPC-induced Ca2+ levels preincubated for 5 mins followed by agonist addition by Fuo-4-AM based spectrofluorimetry2018Journal of medicinal chemistry, 09-27, Volume: 61, Issue:18
Elongation of the Hydrophobic Chain as a Molecular Switch: Discovery of Capsaicin Derivatives and Endogenous Lipids as Potent Transient Receptor Potential Vanilloid Channel 2 Antagonists.
AID1101913Mosquitocidal activity against fourth-instar larvae of Aedes aegypti assessed as mortality after 24 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1212368Drug uptake in albino F344/DuCrlCrlj rat assessed as radioactivity in oleic acid in adipose tissue homogenates at 10 mg/kg, po administered for 5 days by LC-MS/MS spectra analysis2013Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 41, Issue:5
Tissue distribution and identification of radioactivity components at elimination phase after oral administration of [¹⁴C]CS-1036, an α-amylase inhibitor, to rats.
AID627879Inhibition of C-terminal His6-tagged human DNA polymerase kappa (amino acids 1 to 560) using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID307908Displacement of 1,8-ANS from mFABP by fluorescence based-assay2007Bioorganic & medicinal chemistry letters, Jun-15, Volume: 17, Issue:12
Potent and selective biphenyl azole inhibitors of adipocyte fatty acid binding protein (aFABP).
AID1575239Stimulation of human 20S proteasome at 25 uM using 11 amino acid FRET peptide as substrate measured every 2 mins over 1 hr by FRET assay relative to control2019Bioorganic & medicinal chemistry letters, 02-01, Volume: 29, Issue:3
Analysis of chain length, substitution patterns, and unsaturation of AM-404 derivatives as 20S proteasome stimulators.
AID627981Cytotoxicity against mouse RAW264.7 cells2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1901640Agonist activity at human PPARalpha expressed in HEK293 cells by luciferase/beta-galactosidase reporter gene assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID423131Binding affinity to Vibrio cholerae cholera toxin assessed as quenching of intrinsic fluorescence by two-state binding model assay2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID1312082Displacement of 1,8-ANS from His6-tagged FABP4 (unknown origin) R126A mutant expressed in Escherichia coli BL21(DE3) cells at 25 uM by fluorescence assay relative to control2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
AID614103Antimicrobial activity against Candida albicans ATCC 10231 after 24 hrs using thiazoyl blue by agar overlay bioautography method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Tylosema esculentum extractives and their bioactivity.
AID1082324Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under dark conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID319011Activity at gramicidin channel 13 assessed as increase in single channel current2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID1695711Inhibition of LPS-induced TNFalpha production in human THP-1 cells incubated for 2 hrs followed by LPS stimulation and measured after 12 hrs by ELISA2020RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10
Synthesis and biological screening of a library of macamides as TNF-α inhibitors.
AID1312064Displacement of 1,8-ANS from His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells at 25 uM by fluorescence assay relative to control2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
AID1082350Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under dark conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1519393Antibacterial activity against Staphylococcus aureus ATCC 6538 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID319010Effect on gramicidin channel 13 activity2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID1101901Antimicrobial activity against Staphylococcus epidermidis at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1519394Antibacterial activity against Staphylococcus epidermidis ATCC 12228 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID614101Antimicrobial activity against Bacillus subtilis ATCC 6633 after 24 hrs using thiazoyl blue by agar overlay bioautography method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Tylosema esculentum extractives and their bioactivity.
AID423137Binding affinity to enterotoxigenic Escherichia coli 12566 heat-labile enterotoxin assessed as inhibition of heat-labile enterotoxin binding to ganglioside GM1 receptor2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID1617376Drug metabolism in human liver microsomes assessed as microsomal/soluble epoxide hydrolase mediated formation of [+O + H2O] metabolites at 1 uM after 60 mins in presence of NADPH by LC-MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID627976Cytotoxicity against human HCT116 cells by WST-1 assay2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID658577Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of rifampicin-mediated antibacterial activity measuring ratio of rifampicin MIC to rifampicin and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1083130Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1082360Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under light conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082356Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under light conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID780898Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 after 7 days by REMA assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
AID145834Effect on Torpedo nicotinic ACh receptor responses at 0 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID780895Antimycobacterial activity against rifampicin-resistant Mycobacterium tuberculosis ATCC 35338 harboring rpoB His-526-Tir gene mutant after 7 days by REMA assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
AID1101914Nematicidal activity against Panagrellus redivivus assessed as mortality at 100 ug/ml after 24 hr by microscopic analysis2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID658437Antibacterial activity against Mycobacterium smegmatis mc2 155 after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1327077Neuroprotective activity in human SH-SY5Y cells assessed as reduction in 6-OHDA-induced cell death measured after 24 hrs by MTT assay2016Journal of natural products, 08-26, Volume: 79, Issue:8
Chemical Constituents Isolated from the Root Bark of Cudrania tricuspidata and Their Potential Neuroprotective Effects.
AID1083131Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 14 (SDW control = 35.77 +/- 4.48%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID780896Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis 1896HF harboring inhA mutant after 7 days by REMA assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
AID402796Inhibition of amidolytic activity of human recombinant soluble tissue factor (Ala-TF 1 to 219)/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID455081Competitive inhibition of soybean LO1 assessed as increase in arachidonic acid/linoleic acid ratio at 11 uM by substrate specificity assay2009Bioorganic & medicinal chemistry, Sep-15, Volume: 17, Issue:18
Substrate specificity effects of lipoxygenase products and inhibitors on soybean lipoxygenase-1.
AID330321Inhibition of hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum assessed viral RNA level at 0.1 mM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1101903Antimicrobial activity against Escherichia coli at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1083122Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 1000 umol/L after 24 hr Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1082345Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 2% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID627878Inhibition of histidine-tagged human DNA polymerase gamma using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1083125Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 100 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID241990Inhibitory activity against rat liver microsomal Acyl coenzyme A:cholesterol acyltransferase2004Bioorganic & medicinal chemistry letters, Aug-16, Volume: 14, Issue:16
Acyl-CoA: cholesterol acyltransferase inhibitory activities of fatty acid amides isolated from Mylabris phalerate Pallas.
AID1312065Displacement of 1,8-ANS from His6-tagged FABP4 (unknown origin) expressed in Escherichia coli BL21(DE3) cells by fluorescence assay2016Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18
The discovery of novel and selective fatty acid binding protein 4 inhibitors by virtual screening and biological evaluation.
AID627874Inhibition of calf DNA polymerase alpha using poly(dA)/oligo(dT)18 (A/T = 2/1) and dTTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1083120Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 2000 umol/L after 24 hr Rvb = 1.47 to 2.51%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID319017Partition coefficient (x10-4) across dieicosenoyl-phosphatidylcholine bilayer2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID658575Inhibition of Multidrug resistance efflux pump in Mycobacterium smegmatis mc2 155 assessed as modulation of EtBr-mediated antibacterial activity measuring ratio of EtBr MIC to EtBr and compound MIC at 4 mg/L after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Apr-15, Volume: 20, Issue:8
Compounds of Alpinia katsumadai as potential efflux inhibitors in Mycobacterium smegmatis.
AID1885200Binding affinity towards Nurr1 ligand binding domain (unknown origin) measured by tryptophan fluorescence spectroscopy2022Journal of medicinal chemistry, 07-28, Volume: 65, Issue:14
Medicinal Chemistry and Chemical Biology of Nurr1 Modulators: An Emerging Strategy in Neurodegeneration.
AID671698Antiproliferative activity against human SK-N-MC cells after 72 hrs by MTT assay2012Bioorganic & medicinal chemistry, Jan-01, Volume: 20, Issue:1
Investigation of substituted 6-aminohexanoates as skin penetration enhancers.
AID1519398Antibacterial activity against Pseudomonas aeruginosa ATCC 15442 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1083123Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 1000 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID319014Activity at gramicidin channel 13 assessed as increase in single channel current at 10 uM in presence of cholesterol2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID402800Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 90 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID614102Antimicrobial activity against Pseudomonas aeruginosa NCTC 10332 after 24 hrs using thiazoyl blue by agar overlay bioautography method2011Bioorganic & medicinal chemistry, Sep-01, Volume: 19, Issue:17
Tylosema esculentum extractives and their bioactivity.
AID1901633Agonist activity at human PPARalpha transfected in HEK293 cells assessed as relative luciferase unit at 50 uM measured after 16 hrs by luciferase reporter gene assay2022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID196758Tested for inhibition of rat glial cell gap junction at the concentration of 20 uM1999Bioorganic & medicinal chemistry letters, Apr-19, Volume: 9, Issue:8
Arachidonic acid amide inhibitors of gap junction cell-cell communication.
AID360928Inhibition of bovine COX1-mediated prostaglandin biosynthesis using [1-14C]arachidonic acid2001Journal of natural products, Jun, Volume: 64, Issue:6
Cox-2 inhibitory effects of naturally occurring and modified fatty acids.
AID1519399Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 assessed as reduction in bacterial cell growth incubated for 18 hrs by two fold serial microdilution method2020European journal of medicinal chemistry, Jan-01, Volume: 185Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates.
AID1082340Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 5% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082347Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under dark conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1616997Antiallergic activity in rat RBL2H3 cells assessed as inhibition of DNP-HSA-mediated degranulation by measuring decrease in beta-hexosaminidase activity preincubated for 30 mins followed by DNP-HSA stimulation and measured after 30 mins by 4-nitrophenyl 22019Journal of medicinal chemistry, 11-14, Volume: 62, Issue:21
Structure-Activity Relationships of Fish Oil Derivatives with Antiallergic Activity in Vitro and in Vivo.
AID1083133Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 1000 umol/L on day 7 (SDW control = 12.63 +/- 3.84%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID627877Inhibition of calf DNA polymerase alpha using bovine deoxyribonuclease 1-treated DNA and dNTP as the DNA template-primer and nucleotide substrate at 10 uM after 60 mins2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1901643Agonist activity at human PPARalpha expressed in HEK293 cells assessed as maximal activity by luciferase/beta-galactosidase reporter gene assay relative to GW76472022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1083137Nematicidal activity against Meloidogyne incognita (root-knot nematode) root-knot nematodes assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1695710Cytotoxicity against human THP-1 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay2020RSC medicinal chemistry, Oct-01, Volume: 11, Issue:10
Synthesis and biological screening of a library of macamides as TNF-α inhibitors.
AID1101906Antimicrobial activity against Aspergillus flavus at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1083121Nematicidal activity against second-stage juvenile of Meloidogyne incognita (root-knot nematode) assessed as mortality at 25 degC at 2000 umol/L after 12 hr (Rvb = 1.79 to 3.30%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1101916Antimicrobial activity against Pichia kudriavzevii at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID423126Binding affinity to Vibrio cholerae cholera toxin assessed as inhibition of cholera toxin binding to ganglioside GM1 receptor treated 15 mins before receptor addition by ELISA2008Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1
Bile and unsaturated fatty acids inhibit the binding of cholera toxin and Escherichia coli heat-labile enterotoxin to GM1 receptor.
AID1082338Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1083128Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 100 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID483946Displacement of 8-anilino-1-naphthalene-sulfonic acid from human His-FABP4 expressed in Escherichia coli BL21 (DE3) cells at 100 uM after 3 mins2010Bioorganic & medicinal chemistry letters, Jun-15, Volume: 20, Issue:12
Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.
AID1082326Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under light conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082327Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under dark conditions measured 72 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082348Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under dark conditions measured 48 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID330319Increase in hepatitis C virus replication in Huh7-K2040 cells in presence of delipidated fetal calf serum medium at 0.3 uM by RT-PCR relative to control2007Proceedings of the National Academy of Sciences of the United States of America, Nov-20, Volume: 104, Issue:47
Inhibition of hepatitis C virus replication by peroxidation of arachidonate and restoration by vitamin E.
AID1509163Displacement of 3[H]retinol from human biotinylated RBP4 after overnight incubation by surface plasmon resonance analysis2019Journal of medicinal chemistry, 06-13, Volume: 62, Issue:11
Design, Synthesis, and Preclinical Efficacy of Novel Nonretinoid Antagonists of Retinol-Binding Protein 4 in the Mouse Model of Hepatic Steatosis.
AID1083135Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 3 (SDW control = 0.57 +/- 0.37%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID1101907Antimicrobial activity against Candida albicans at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID1901645Agonist activity at human PPARdelta expressed in HEK293 cells assessed as maximal activity by luciferase/beta-galactosidase reporter gene assay relative to GW07422022Journal of medicinal chemistry, 02-10, Volume: 65, Issue:3
Phenolic Lipids Derived from Cashew Nut Shell Liquid to Treat Metabolic Diseases.
AID1617375Drug metabolism in human liver microsomes assessed as CYP450-mediated formation of [+O] metabolites at 1 uM after 60 mins in absence of NADPH by LC-MS analysis2019Journal of medicinal chemistry, 11-27, Volume: 62, Issue:22
Development of Robust 17(
AID1082352Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 1% under dark conditions measured 24 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID402799Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with tissue factor for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID407371Binding affinity to L-FABP low binding affinity site by titration calorimetry method2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID145835Effect on Torpedo nicotinic ACh receptor responses at 10 min determined by measuring percentage of original amplitude2003Bioorganic & medicinal chemistry letters, Mar-24, Volume: 13, Issue:6
The newly synthesized linoleic acid derivative FR236924 induces a long-lasting facilitation of hippocampal neurotransmission by targeting nicotinic acetylcholine receptors.
AID1082341Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.125% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID402795Inhibition of amidolytic activity of human tissue factor/human factor 7a1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1082339Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 2% under dark conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID780897Antimycobacterial activity against isoniazid-resistant Mycobacterium tuberculosis ATCC 35822 harboring katG mutant after 7 days by REMA assay2013Bioorganic & medicinal chemistry, Nov-15, Volume: 21, Issue:22
Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
AID1082332Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 0.25% under light conditions measured 72 hr post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID1082346Nematicidal activity against Heterodera zeae infective stage larvae assessed as nematode mortality at 5% under light conditions measured 5 to 60 min post dose by stereoscopic microscopy2011Journal of agricultural and food chemistry, Sep-14, Volume: 59, Issue:17
Isolation of nematicidal compounds from Tagetes patula L. yellow flowers: structure-activity relationship studies against cyst nematode Heterodera zeae infective stage larvae.
AID627979Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced TNFalpha secretion at 5 uM treated 30 mins before LPS challenge measured after 24 hrs by ELISA2011Bioorganic & medicinal chemistry, Oct-01, Volume: 19, Issue:19
Inhibitory effect of novel 5-O-acyl juglones on mammalian DNA polymerase activity, cancer cell growth and inflammatory response.
AID1446793Binding affinity to RXR (unknown origin)2017Journal of medicinal chemistry, 07-13, Volume: 60, Issue:13
Opportunities and Challenges for Fatty Acid Mimetics in Drug Discovery.
AID1083126Nematicidal activity against Meloidogyne incognita (root-knot nematode) assessed as cumulative percentage of egg hatching at 25 degC at 2000 umol/L on day 21 (SDW control = 44.87 +/- 3.93%)2012Journal of agricultural and food chemistry, Nov-21, Volume: 60, Issue:46
Potential antagonistic effects of nine natural fatty acids against Meloidogyne incognita.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID407366Displacement of 1-anilinonaphthalene-8-sulphonic acid from rat recombinant L-FABP high binding affinity site expressed in Escherichia coli BL21 by competitive fluorescence displacement assay2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
AID1101902Antimicrobial activity against Staphylococcus aureus at 100 ug/ml after 72 hr2002Journal of agricultural and food chemistry, Jul-31, Volume: 50, Issue:16
Pest-managing efficacy of trans-asarone isolated from Daucus carota L. seeds.
AID402793Inhibition of pig pancreatic trypsin after 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID361445Inhibition of DNA topoisomerase 12002Journal of natural products, Nov, Volume: 65, Issue:11
Total synthesis and biological evaluation of (5Z,9Z)-5,9-hexadecadienoic acid, an inhibitor of human topoisomerase I.
AID356414Induction of NADPH:quinone reductase activity in mouse Hepa-1c1c7 cells assessed as drug level required to double specific enzyme activity2003Journal of natural products, Sep, Volume: 66, Issue:9
Constituents of the stem bark of Pongamia pinnata with the potential to induce quinone reductase.
AID402797Inhibition of amidolytic activity of human recombinant soluble tissue factor/human factor 7a preincubated with factor 7a for 15 mins1998Journal of natural products, Nov, Volume: 61, Issue:11
Inhibitory activity of unsaturated fatty acids and anacardic acids toward soluble tissue factor-factor VIIa complex.
AID319013Activity at gramicidin channel 13 assessed as increase in single channel current at 10 uM2007Proceedings of the National Academy of Sciences of the United States of America, Jun-05, Volume: 104, Issue:23
Docosahexaenoic acid alters bilayer elastic properties.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2001Journal of molecular biology, Dec-14, Volume: 314, Issue:5
Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.
AID1811Experimentally measured binding affinity data derived from PDB2001Journal of molecular biology, Dec-14, Volume: 314, Issue:5
Crystal structures of human serum albumin complexed with monounsaturated and polyunsaturated fatty acids.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003Biochemical and biophysical research communications, Feb-07, Volume: 301, Issue:2
A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs.
AID1345188Human FFA4 receptor (Free fatty acid receptors)2012Molecular pharmacology, May, Volume: 81, Issue:5
Differential signaling by splice variants of the human free fatty acid receptor GPR120.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003The Journal of biological chemistry, Mar-28, Volume: 278, Issue:13
The orphan G protein-coupled receptor GPR40 is activated by medium and long chain fatty acids.
AID1345285Human PLD2 (Hydrolases)2003The Biochemical journal, Jan-15, Volume: 369, Issue:Pt 2
Endogenous phospholipase D2 localizes to the plasma membrane of RBL-2H3 mast cells and can be distinguished from ADP ribosylation factor-stimulated phospholipase D1 activity by its specific sensitivity to oleic acid.
AID1345809Human FFA1 receptor (Free fatty acid receptors)2003Nature, Mar-13, Volume: 422, Issue:6928
Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40.
AID1811Experimentally measured binding affinity data derived from PDB1994Structure (London, England : 1993), Jun-15, Volume: 2, Issue:6
Structural studies on human muscle fatty acid binding protein at 1.4 A resolution: binding interactions with three C18 fatty acids.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB1994Structure (London, England : 1993), Jun-15, Volume: 2, Issue:6
Structural studies on human muscle fatty acid binding protein at 1.4 A resolution: binding interactions with three C18 fatty acids.
AID1811Experimentally measured binding affinity data derived from PDB2004Journal of lipid research, Feb, Volume: 45, Issue:2
Specificity determinants for lipids bound to beta-barrel proteins.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2004Journal of lipid research, Feb, Volume: 45, Issue:2
Specificity determinants for lipids bound to beta-barrel proteins.
AID977611Experimentally measured binding affinity data (Kd) for protein-ligand complexes derived from PDB2008Journal of medicinal chemistry, Jul-10, Volume: 51, Issue:13
Characterization of the drug binding specificity of rat liver fatty acid binding protein.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8,534)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901557 (18.24)18.7374
1990's1774 (20.79)18.2507
2000's1926 (22.57)29.6817
2010's2495 (29.24)24.3611
2020's782 (9.16)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials248 (2.83%)5.53%
Reviews144 (1.64%)6.00%
Case Studies17 (0.19%)4.05%
Observational3 (0.03%)0.25%
Other8,356 (95.30%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]